KR20070038500A - ｅｒｂＢ 수용체 타이로신 키나제로서의 퀴나졸린 유도체 - Google Patents

Info

Publication number

KR20070038500A

KR20070038500A KR1020077000221A KR20077000221A KR20070038500A KR 20070038500 A KR20070038500 A KR 20070038500A KR 1020077000221 A KR1020077000221 A KR 1020077000221A KR 20077000221 A KR20077000221 A KR 20077000221A KR 20070038500 A KR20070038500 A KR 20070038500A

Authority

KR

South Korea

Prior art keywords

oxy

alkyl

methyl

quinazolin

phenyl

Prior art date

2004-06-04

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Withdrawn

Links

• Espacenet
• Global Dossier
• Discuss

• 125000002294 quinazolinyl group Chemical class N1=C(N=CC2=CC=CC=C12)* 0.000 title abstract description 119
• 102000004022 Protein-Tyrosine Kinases Human genes 0.000 title description 20
• 108090000412 Protein-Tyrosine Kinases Proteins 0.000 title description 20
• 238000000034 method Methods 0.000 claims abstract description 77
• 230000001028 anti-proliverative effect Effects 0.000 claims abstract description 6
• 239000003814 drug Substances 0.000 claims abstract description 4
• 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 3
• 125000000217 alkyl group Chemical group 0.000 claims description 795
• -1 cyano, nitro, hydroxy, amino, carboxy, carbamoyl Chemical group 0.000 claims description 707
• 125000001424 substituent group Chemical group 0.000 claims description 343
• 229910052757 nitrogen Inorganic materials 0.000 claims description 337
• 125000000623 heterocyclic group Chemical group 0.000 claims description 279
• 239000001257 hydrogen Substances 0.000 claims description 179
• 229910052739 hydrogen Inorganic materials 0.000 claims description 179
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 163
• 125000003545 alkoxy group Chemical group 0.000 claims description 162
• 125000004433 nitrogen atom Chemical group N* 0.000 claims description 140
• 125000005843 halogen group Chemical group 0.000 claims description 137
• 229910052760 oxygen Inorganic materials 0.000 claims description 106
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 104
• 125000000304 alkynyl group Chemical group 0.000 claims description 100
• 125000003342 alkenyl group Chemical group 0.000 claims description 98
• 125000003282 alkyl amino group Chemical group 0.000 claims description 92
• 150000001875 compounds Chemical class 0.000 claims description 90
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 87
• 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 80
• 238000006243 chemical reaction Methods 0.000 claims description 79
• 125000001589 carboacyl group Chemical group 0.000 claims description 63
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 62
• 150000003839 salts Chemical class 0.000 claims description 61
• XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 60
• 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 59
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 59
• 125000005842 heteroatom Chemical group 0.000 claims description 59
• 125000004093 cyano group Chemical group *C#N 0.000 claims description 56
• 125000001153 fluoro group Chemical group F* 0.000 claims description 56
• 239000001301 oxygen Substances 0.000 claims description 56
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 56
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 55
• 229910052717 sulfur Inorganic materials 0.000 claims description 53
• 125000001309 chloro group Chemical group Cl* 0.000 claims description 52
• 229910005965 SO 2 Inorganic materials 0.000 claims description 48
• 125000005236 alkanoylamino group Chemical group 0.000 claims description 48
• 125000000753 cycloalkyl group Chemical group 0.000 claims description 47
• 125000004656 alkyl sulfonylamino group Chemical group 0.000 claims description 46
• 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims description 46
• 230000008569 process Effects 0.000 claims description 43
• 125000004644 alkyl sulfinyl group Chemical group 0.000 claims description 40
• 125000004414 alkyl thio group Chemical group 0.000 claims description 40
• 125000004423 acyloxy group Chemical group 0.000 claims description 39
• 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 38
• 150000001412 amines Chemical class 0.000 claims description 37
• 229910002091 carbon monoxide Inorganic materials 0.000 claims description 37
• 125000004043 oxo group Chemical group O=* 0.000 claims description 36
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 35
• 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 35
• 229920006395 saturated elastomer Polymers 0.000 claims description 33
• 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims description 30
• 125000000524 functional group Chemical group 0.000 claims description 30
• 125000004076 pyridyl group Chemical group 0.000 claims description 30
• JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 claims description 30
• 239000011593 sulfur Chemical group 0.000 claims description 30
• NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 29
• 125000005153 alkyl sulfamoyl group Chemical group 0.000 claims description 29
• 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 29
• 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 26
• 125000005115 alkyl carbamoyl group Chemical group 0.000 claims description 24
• 229910052799 carbon Inorganic materials 0.000 claims description 24
• OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Natural products OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 24
• 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims description 24
• 125000003396 thiol group Chemical class [H]S* 0.000 claims description 22
• 125000003118 aryl group Chemical group 0.000 claims description 20
• 125000004448 alkyl carbonyl group Chemical group 0.000 claims description 19
• 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 17
• 125000000714 pyrimidinyl group Chemical group 0.000 claims description 17
• 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 claims description 16
• 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims description 16
• 150000002431 hydrogen Chemical class 0.000 claims description 16
• 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims description 16
• 125000003386 piperidinyl group Chemical group 0.000 claims description 16
• 125000003373 pyrazinyl group Chemical group 0.000 claims description 16
• 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 claims description 15
• 125000001072 heteroaryl group Chemical group 0.000 claims description 15
• 230000002401 inhibitory effect Effects 0.000 claims description 15
• 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 15
• 125000000392 cycloalkenyl group Chemical group 0.000 claims description 14
• 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 14
• 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 14
• 125000006239 protecting group Chemical group 0.000 claims description 14
• 125000000000 cycloalkoxy group Chemical group 0.000 claims description 13
• XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 claims description 13
• 125000004566 azetidin-1-yl group Chemical group N1(CCC1)* 0.000 claims description 12
• 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 12
• 125000002098 pyridazinyl group Chemical group 0.000 claims description 11
• 239000000126 substance Substances 0.000 claims description 11
• 125000002393 azetidinyl group Chemical group 0.000 claims description 10
• 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 claims description 10
• QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 claims description 10
• 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 claims description 10
• 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 10
• DRYRBWIFRVMRPV-UHFFFAOYSA-N quinazolin-4-amine Chemical compound C1=CC=C2C(N)=NC=NC2=C1 DRYRBWIFRVMRPV-UHFFFAOYSA-N 0.000 claims description 10
• 125000001412 tetrahydropyranyl group Chemical group 0.000 claims description 10
• 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 claims description 9
• HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 claims description 9
• 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 9
• 125000004432 carbon atom Chemical group C* 0.000 claims description 9
• 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 9
• 125000002534 ethynyl group Chemical group [H]C#C* 0.000 claims description 9
• 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims description 9
• 229920002554 vinyl polymer Polymers 0.000 claims description 9
• 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims description 8
• 101710100968 Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims description 8
• 125000003302 alkenyloxy group Chemical group 0.000 claims description 8
• 125000005133 alkynyloxy group Chemical group 0.000 claims description 8
• 125000001246 bromo group Chemical group Br* 0.000 claims description 8
• 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 claims description 8
• ATUOYWHBWRKTHZ-UHFFFAOYSA-N dimethylmethane Natural products CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 claims description 8
• 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 8
• 239000001294 propane Substances 0.000 claims description 8
• 125000001422 pyrrolinyl group Chemical group 0.000 claims description 8
• ZMANZCXQSJIPKH-UHFFFAOYSA-N triethylamine Natural products CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 8
• 241001465754 Metazoa Species 0.000 claims description 7
• 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 7
• 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims description 7
• 125000005958 tetrahydrothienyl group Chemical group 0.000 claims description 7
• QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 claims description 6
• 241000156724 Antirhea Species 0.000 claims description 6
• 239000007822 coupling agent Substances 0.000 claims description 6
• 125000004655 dihydropyridinyl group Chemical group N1(CC=CC=C1)* 0.000 claims description 6
• 125000005053 dihydropyrimidinyl group Chemical group N1(CN=CC=C1)* 0.000 claims description 6
• 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 6
• 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 claims description 6
• 125000004853 tetrahydropyridinyl group Chemical group N1(CCCC=C1)* 0.000 claims description 6
• 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 claims description 6
• 239000012190 activator Substances 0.000 claims description 5
• 150000001408 amides Chemical class 0.000 claims description 5
• 125000004850 cyclobutylmethyl group Chemical group C1(CCC1)C* 0.000 claims description 5
• 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 5
• 125000004851 cyclopentylmethyl group Chemical group C1(CCCC1)C* 0.000 claims description 5
• 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 claims description 5
• 125000005745 ethoxymethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])* 0.000 claims description 5
• 125000006173 tetrahydropyranylmethyl group Chemical group 0.000 claims description 5
• BTNBMGWBIOYPAU-FXAWDEMLSA-N (2s)-2-[4-[3-chloro-4-(pyridin-2-ylmethoxy)anilino]quinazolin-5-yl]oxy-1-[(3r)-3-hydroxypyrrolidin-1-yl]propan-1-one Chemical compound O([C@@H](C)C(=O)N1C[C@H](O)CC1)C(C=12)=CC=CC2=NC=NC=1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 BTNBMGWBIOYPAU-FXAWDEMLSA-N 0.000 claims description 4
• BTNBMGWBIOYPAU-PXNSSMCTSA-N (2s)-2-[4-[3-chloro-4-(pyridin-2-ylmethoxy)anilino]quinazolin-5-yl]oxy-1-[(3s)-3-hydroxypyrrolidin-1-yl]propan-1-one Chemical compound O([C@@H](C)C(=O)N1C[C@@H](O)CC1)C(C=12)=CC=CC2=NC=NC=1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 BTNBMGWBIOYPAU-PXNSSMCTSA-N 0.000 claims description 4
• 238000005859 coupling reaction Methods 0.000 claims description 4
• 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims description 4
• 125000006125 ethylsulfonyl group Chemical group 0.000 claims description 4
• 238000004519 manufacturing process Methods 0.000 claims description 4
• 125000006223 tetrahydrofuranylmethyl group Chemical group 0.000 claims description 4
• 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 claims description 3
• 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 claims description 3
• ZBYCKCQLRHBIOI-JOCHJYFZSA-N (2r)-1-(4-ethylpiperazin-1-yl)-2-[4-[3-methyl-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-5-yl]oxypropan-1-one Chemical compound C1CN(CC)CCN1C(=O)[C@@H](C)OC1=CC=CC2=NC=NC(NC=3C=C(C)C(OC=4C=NC(C)=CC=4)=CC=3)=C12 ZBYCKCQLRHBIOI-JOCHJYFZSA-N 0.000 claims description 2
• UXGHRLFRUHPVAO-HXUWFJFHSA-N (2r)-1-(4-hydroxypiperidin-1-yl)-2-[4-[3-methyl-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-5-yl]oxypropan-1-one Chemical compound O([C@H](C)C(=O)N1CCC(O)CC1)C(C=12)=CC=CC2=NC=NC=1NC(C=C1C)=CC=C1OC1=CC=C(C)N=C1 UXGHRLFRUHPVAO-HXUWFJFHSA-N 0.000 claims description 2
• POQPMXJVRGTDHK-LJQANCHMSA-N (2r)-1-(azetidin-1-yl)-2-[4-[3-methyl-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-5-yl]oxypropan-1-one Chemical compound O([C@H](C)C(=O)N1CCC1)C(C=12)=CC=CC2=NC=NC=1NC(C=C1C)=CC=C1OC1=CC=C(C)N=C1 POQPMXJVRGTDHK-LJQANCHMSA-N 0.000 claims description 2
• WHSWMMPWNOZHIK-IFMALSPDSA-N (2r)-1-[(2r)-2-(hydroxymethyl)pyrrolidin-1-yl]-2-[4-[3-methyl-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-5-yl]oxypropan-1-one Chemical compound O([C@H](C)C(=O)N1[C@H](CCC1)CO)C(C=12)=CC=CC2=NC=NC=1NC(C=C1C)=CC=C1OC1=CC=C(C)N=C1 WHSWMMPWNOZHIK-IFMALSPDSA-N 0.000 claims description 2
• WHSWMMPWNOZHIK-IRLDBZIGSA-N (2r)-1-[(2s)-2-(hydroxymethyl)pyrrolidin-1-yl]-2-[4-[3-methyl-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-5-yl]oxypropan-1-one Chemical compound O([C@H](C)C(=O)N1[C@@H](CCC1)CO)C(C=12)=CC=CC2=NC=NC=1NC(C=C1C)=CC=C1OC1=CC=C(C)N=C1 WHSWMMPWNOZHIK-IRLDBZIGSA-N 0.000 claims description 2
• BHKXUDXNCBTWQC-TZIWHRDSSA-N (2r)-1-[(3r)-3-hydroxypiperidin-1-yl]-2-[4-(3-methyl-4-pyridin-2-yloxyanilino)quinazolin-5-yl]oxypropan-1-one Chemical compound O([C@H](C)C(=O)N1C[C@H](O)CCC1)C(C=12)=CC=CC2=NC=NC=1NC(C=C1C)=CC=C1OC1=CC=CC=N1 BHKXUDXNCBTWQC-TZIWHRDSSA-N 0.000 claims description 2
• WACRWIYZJJPTCG-TZIWHRDSSA-N (2r)-1-[(3r)-3-hydroxypiperidin-1-yl]-2-[4-[3-methoxy-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-5-yl]oxypropan-1-one Chemical compound O=C([C@@H](C)OC=1C=CC=C2N=CN=C(C=12)NC=1C=C(C(=CC=1)OC=1C=NC(C)=CC=1)OC)N1CCC[C@@H](O)C1 WACRWIYZJJPTCG-TZIWHRDSSA-N 0.000 claims description 2
• HACPXTPHGGTGJL-IFMALSPDSA-N (2r)-1-[(3r)-3-hydroxypiperidin-1-yl]-2-[4-[3-methyl-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-5-yl]oxypropan-1-one Chemical compound O([C@H](C)C(=O)N1C[C@H](O)CCC1)C(C=12)=CC=CC2=NC=NC=1NC(C=C1C)=CC=C1OC1=CC=C(C)N=C1 HACPXTPHGGTGJL-IFMALSPDSA-N 0.000 claims description 2
• CUXVZRKCEYEHCD-TZIWHRDSSA-N (2r)-1-[(3r)-3-hydroxypyrrolidin-1-yl]-2-[4-[3-methyl-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-5-yl]oxypropan-1-one Chemical compound O([C@H](C)C(=O)N1C[C@H](O)CC1)C(C=12)=CC=CC2=NC=NC=1NC(C=C1C)=CC=C1OC1=CC=C(C)N=C1 CUXVZRKCEYEHCD-TZIWHRDSSA-N 0.000 claims description 2
• DTKCUTKZQAYHLJ-DENIHFKCSA-N (2r)-1-[(3r)-3-hydroxypyrrolidin-1-yl]-2-[4-[3-methyl-4-(pyridin-2-ylmethoxy)anilino]quinazolin-5-yl]oxypropan-1-one Chemical compound O([C@H](C)C(=O)N1C[C@H](O)CC1)C(C=12)=CC=CC2=NC=NC=1NC(C=C1C)=CC=C1OCC1=CC=CC=N1 DTKCUTKZQAYHLJ-DENIHFKCSA-N 0.000 claims description 2
• HACPXTPHGGTGJL-IRLDBZIGSA-N (2r)-1-[(3s)-3-hydroxypiperidin-1-yl]-2-[4-[3-methyl-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-5-yl]oxypropan-1-one Chemical compound O([C@H](C)C(=O)N1C[C@@H](O)CCC1)C(C=12)=CC=CC2=NC=NC=1NC(C=C1C)=CC=C1OC1=CC=C(C)N=C1 HACPXTPHGGTGJL-IRLDBZIGSA-N 0.000 claims description 2
• CUXVZRKCEYEHCD-CTNGQTDRSA-N (2r)-1-[(3s)-3-hydroxypyrrolidin-1-yl]-2-[4-[3-methyl-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-5-yl]oxypropan-1-one Chemical compound O([C@H](C)C(=O)N1C[C@@H](O)CC1)C(C=12)=CC=CC2=NC=NC=1NC(C=C1C)=CC=C1OC1=CC=C(C)N=C1 CUXVZRKCEYEHCD-CTNGQTDRSA-N 0.000 claims description 2
• STTQEGIPIRVTBK-OAQYLSRUSA-N (2r)-1-[4-(hydroxymethyl)piperidin-1-yl]-2-[4-[3-methyl-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-5-yl]oxypropan-1-one Chemical compound O([C@H](C)C(=O)N1CCC(CO)CC1)C(C=12)=CC=CC2=NC=NC=1NC(C=C1C)=CC=C1OC1=CC=C(C)N=C1 STTQEGIPIRVTBK-OAQYLSRUSA-N 0.000 claims description 2
• YHXQGEWKBGXUHP-GOSISDBHSA-N (2r)-1-morpholin-4-yl-2-[4-(4-pyridin-3-yloxyanilino)quinazolin-5-yl]oxypropan-1-one Chemical compound O([C@H](C)C(=O)N1CCOCC1)C(C=12)=CC=CC2=NC=NC=1NC(C=C1)=CC=C1OC1=CC=CN=C1 YHXQGEWKBGXUHP-GOSISDBHSA-N 0.000 claims description 2
• BUVVFLDHQZDVQL-DUSLRRAJSA-N (2r)-2-[4-(3-chloro-4-pyridin-2-yloxyanilino)quinazolin-5-yl]oxy-1-(3-hydroxypiperidin-1-yl)propan-1-one Chemical compound O([C@H](C)C(=O)N1CC(O)CCC1)C(C=12)=CC=CC2=NC=NC=1NC(C=C1Cl)=CC=C1OC1=CC=CC=N1 BUVVFLDHQZDVQL-DUSLRRAJSA-N 0.000 claims description 2
• GQGOLYCZKGIRHT-OAHLLOKOSA-N (2r)-2-[4-(3-chloro-4-pyridin-2-yloxyanilino)quinazolin-5-yl]oxy-n,n-dimethylpropanamide Chemical compound C=12C(O[C@H](C)C(=O)N(C)C)=CC=CC2=NC=NC=1NC(C=C1Cl)=CC=C1OC1=CC=CC=N1 GQGOLYCZKGIRHT-OAHLLOKOSA-N 0.000 claims description 2
• BSMOUWVKFROESP-MRXNPFEDSA-N (2r)-2-[4-(3-chloro-4-pyridin-2-yloxyanilino)quinazolin-5-yl]oxy-n-(2-hydroxyethyl)-n-methylpropanamide Chemical compound C=12C(O[C@H](C)C(=O)N(C)CCO)=CC=CC2=NC=NC=1NC(C=C1Cl)=CC=C1OC1=CC=CC=N1 BSMOUWVKFROESP-MRXNPFEDSA-N 0.000 claims description 2
• WEZZNWQATVXVDW-QGZVFWFLSA-N (2r)-2-[4-(3-fluoro-4-pyridin-3-yloxyanilino)quinazolin-5-yl]oxy-1-morpholin-4-ylpropan-1-one Chemical compound O([C@H](C)C(=O)N1CCOCC1)C(C=12)=CC=CC2=NC=NC=1NC(C=C1F)=CC=C1OC1=CC=CN=C1 WEZZNWQATVXVDW-QGZVFWFLSA-N 0.000 claims description 2
• OAWKJLALCNLYTB-GOSISDBHSA-N (2r)-2-[4-(3-methoxy-4-pyridin-3-yloxyanilino)quinazolin-5-yl]oxy-1-morpholin-4-ylpropan-1-one Chemical compound O=C([C@@H](C)OC=1C=CC=C2N=CN=C(C=12)NC=1C=C(C(=CC=1)OC=1C=NC=CC=1)OC)N1CCOCC1 OAWKJLALCNLYTB-GOSISDBHSA-N 0.000 claims description 2
• RFHNMCRURAMFHZ-GOSISDBHSA-N (2r)-2-[4-(3-methyl-4-pyridazin-3-yloxyanilino)quinazolin-5-yl]oxy-1-morpholin-4-ylpropan-1-one Chemical compound O([C@H](C)C(=O)N1CCOCC1)C(C=12)=CC=CC2=NC=NC=1NC(C=C1C)=CC=C1OC1=CC=CN=N1 RFHNMCRURAMFHZ-GOSISDBHSA-N 0.000 claims description 2
• CQLYORSHVYBLMS-GOSISDBHSA-N (2r)-2-[4-(3-methyl-4-pyrimidin-5-yloxyanilino)quinazolin-5-yl]oxy-1-morpholin-4-ylpropan-1-one Chemical compound O([C@H](C)C(=O)N1CCOCC1)C(C=12)=CC=CC2=NC=NC=1NC(C=C1C)=CC=C1OC1=CN=CN=C1 CQLYORSHVYBLMS-GOSISDBHSA-N 0.000 claims description 2
• TYPJWHGRDVHRRZ-OAHLLOKOSA-N (2r)-2-[4-[3-chloro-4-(1,3-thiazol-2-yloxy)anilino]quinazolin-5-yl]oxy-1-morpholin-4-ylpropan-1-one Chemical compound O([C@H](C)C(=O)N1CCOCC1)C(C=12)=CC=CC2=NC=NC=1NC(C=C1Cl)=CC=C1OC1=NC=CS1 TYPJWHGRDVHRRZ-OAHLLOKOSA-N 0.000 claims description 2
• BKUNUATYQBJKAW-MRXNPFEDSA-N (2r)-2-[4-[3-chloro-4-(1-methylpyrazol-4-yl)oxyanilino]quinazolin-5-yl]oxy-1-morpholin-4-ylpropan-1-one Chemical compound O([C@H](C)C(=O)N1CCOCC1)C(C=12)=CC=CC2=NC=NC=1NC(C=C1Cl)=CC=C1OC=1C=NN(C)C=1 BKUNUATYQBJKAW-MRXNPFEDSA-N 0.000 claims description 2
• CTFGDXFXTZFJLD-GOSISDBHSA-N (2r)-2-[4-[3-chloro-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-5-yl]oxy-1-morpholin-4-ylpropan-1-one Chemical compound O([C@H](C)C(=O)N1CCOCC1)C(C=12)=CC=CC2=NC=NC=1NC(C=C1Cl)=CC=C1OC1=CC=C(C)N=C1 CTFGDXFXTZFJLD-GOSISDBHSA-N 0.000 claims description 2
• DYOHMTPFQDFJSG-MRXNPFEDSA-N (2r)-2-[4-[3-chloro-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-5-yl]oxy-n,n-dimethylpropanamide Chemical compound C=12C(O[C@H](C)C(=O)N(C)C)=CC=CC2=NC=NC=1NC(C=C1Cl)=CC=C1OC1=CC=C(C)N=C1 DYOHMTPFQDFJSG-MRXNPFEDSA-N 0.000 claims description 2
• ZGBFXAWADCAOJE-QGZVFWFLSA-N (2r)-2-[4-[3-chloro-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-5-yl]oxy-n-(2-hydroxyethyl)-n-methylpropanamide Chemical compound C=12C(O[C@H](C)C(=O)N(C)CCO)=CC=CC2=NC=NC=1NC(C=C1Cl)=CC=C1OC1=CC=C(C)N=C1 ZGBFXAWADCAOJE-QGZVFWFLSA-N 0.000 claims description 2
• BTNBMGWBIOYPAU-YLJYHZDGSA-N (2r)-2-[4-[3-chloro-4-(pyridin-2-ylmethoxy)anilino]quinazolin-5-yl]oxy-1-[(3r)-3-hydroxypyrrolidin-1-yl]propan-1-one Chemical compound O([C@H](C)C(=O)N1C[C@H](O)CC1)C(C=12)=CC=CC2=NC=NC=1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 BTNBMGWBIOYPAU-YLJYHZDGSA-N 0.000 claims description 2
• UTHNMKVUDJYYFU-GOSISDBHSA-N (2r)-2-[4-[3-chloro-4-(pyridin-2-ylmethoxy)anilino]quinazolin-5-yl]oxy-1-pyrrolidin-1-ylpropan-1-one Chemical compound O([C@H](C)C(=O)N1CCCC1)C(C=12)=CC=CC2=NC=NC=1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 UTHNMKVUDJYYFU-GOSISDBHSA-N 0.000 claims description 2
• FYQLSGTZXNFLBP-AREMUKBSSA-N (2r)-2-[4-[3-chloro-4-(pyridin-2-ylmethoxy)anilino]quinazolin-5-yl]oxy-4-hydroxy-1-(4-methylpiperazin-1-yl)butan-1-one Chemical compound C1CN(C)CCN1C(=O)[C@@H](CCO)OC1=CC=CC2=NC=NC(NC=3C=C(Cl)C(OCC=4N=CC=CC=4)=CC=3)=C12 FYQLSGTZXNFLBP-AREMUKBSSA-N 0.000 claims description 2
• KXKMLDJBINFBMA-RUZDIDTESA-N (2r)-2-[4-[3-chloro-4-(pyridin-2-ylmethoxy)anilino]quinazolin-5-yl]oxy-4-hydroxy-1-morpholin-4-ylbutan-1-one Chemical compound O([C@H](CCO)C(=O)N1CCOCC1)C(C=12)=CC=CC2=NC=NC=1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 KXKMLDJBINFBMA-RUZDIDTESA-N 0.000 claims description 2
• CBUHIHJVWPRZBD-RUZDIDTESA-N (2r)-2-[4-[3-chloro-4-(pyridin-2-ylmethoxy)anilino]quinazolin-5-yl]oxy-4-hydroxy-1-pyrrolidin-1-ylbutan-1-one Chemical compound O([C@H](CCO)C(=O)N1CCCC1)C(C=12)=CC=CC2=NC=NC=1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 CBUHIHJVWPRZBD-RUZDIDTESA-N 0.000 claims description 2
• UFOUYPHVNFLZQT-HSZRJFAPSA-N (2r)-2-[4-[3-chloro-4-(pyridin-2-ylmethoxy)anilino]quinazolin-5-yl]oxy-4-hydroxy-n,n-dimethylbutanamide Chemical compound C=12C(O[C@H](CCO)C(=O)N(C)C)=CC=CC2=NC=NC=1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 UFOUYPHVNFLZQT-HSZRJFAPSA-N 0.000 claims description 2
• WVPHLDMWUKZQRT-XMMPIXPASA-N (2r)-2-[4-[3-chloro-4-(pyridin-2-ylmethoxy)anilino]quinazolin-5-yl]oxy-4-hydroxy-n-(2-hydroxyethyl)-n-methylbutanamide Chemical compound C=12C(O[C@H](CCO)C(=O)N(CCO)C)=CC=CC2=NC=NC=1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 WVPHLDMWUKZQRT-XMMPIXPASA-N 0.000 claims description 2
• LAOAMPGLBWUUOH-JOCHJYFZSA-N (2r)-2-[4-[3-chloro-4-(pyridin-2-ylmethoxy)anilino]quinazolin-5-yl]oxy-4-hydroxy-n-methylbutanamide Chemical compound C=12C(O[C@H](CCO)C(=O)NC)=CC=CC2=NC=NC=1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 LAOAMPGLBWUUOH-JOCHJYFZSA-N 0.000 claims description 2
• QPPYSOHWFOUKPX-MRXNPFEDSA-N (2r)-2-[4-[3-chloro-4-(pyridin-2-ylmethoxy)anilino]quinazolin-5-yl]oxy-n,n-dimethylpropanamide Chemical compound C=12C(O[C@H](C)C(=O)N(C)C)=CC=CC2=NC=NC=1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 QPPYSOHWFOUKPX-MRXNPFEDSA-N 0.000 claims description 2
• WZEUNGUUUBFSGF-QGZVFWFLSA-N (2r)-2-[4-[3-chloro-4-(pyridin-2-ylmethoxy)anilino]quinazolin-5-yl]oxy-n-(2-hydroxyethyl)-n-methylpropanamide Chemical compound C=12C(O[C@H](C)C(=O)N(C)CCO)=CC=CC2=NC=NC=1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 WZEUNGUUUBFSGF-QGZVFWFLSA-N 0.000 claims description 2
• QCTACFWJSRSNOJ-OAHLLOKOSA-N (2r)-2-[4-[3-chloro-4-(pyridin-2-ylmethoxy)anilino]quinazolin-5-yl]oxy-n-methylpropanamide Chemical compound C=12C(O[C@H](C)C(=O)NC)=CC=CC2=NC=NC=1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 QCTACFWJSRSNOJ-OAHLLOKOSA-N 0.000 claims description 2
• DMWWQRAYTXZZJP-CQSZACIVSA-N (2r)-2-[4-[3-chloro-4-(pyridin-2-ylmethoxy)anilino]quinazolin-5-yl]oxypropanamide Chemical compound C=12C(O[C@H](C)C(N)=O)=CC=CC2=NC=NC=1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 DMWWQRAYTXZZJP-CQSZACIVSA-N 0.000 claims description 2
• ZIHGLKQTSBXMBZ-QGZVFWFLSA-N (2r)-2-[4-[3-methoxy-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-5-yl]oxy-n,n-dimethylpropanamide Chemical compound COC1=CC(NC=2C3=C(O[C@H](C)C(=O)N(C)C)C=CC=C3N=CN=2)=CC=C1OC1=CC=C(C)N=C1 ZIHGLKQTSBXMBZ-QGZVFWFLSA-N 0.000 claims description 2
• CLVHWHRMEZJEAB-QGZVFWFLSA-N (2r)-2-[4-[3-methyl-4-(1,3-thiazol-2-yloxy)anilino]quinazolin-5-yl]oxy-1-morpholin-4-ylpropan-1-one Chemical compound O([C@H](C)C(=O)N1CCOCC1)C(C=12)=CC=CC2=NC=NC=1NC(C=C1C)=CC=C1OC1=NC=CS1 CLVHWHRMEZJEAB-QGZVFWFLSA-N 0.000 claims description 2
• AMBLTSYRYALCDZ-QGZVFWFLSA-N (2r)-2-[4-[3-methyl-4-(1,3-thiazol-5-yloxy)anilino]quinazolin-5-yl]oxy-1-morpholin-4-ylpropan-1-one Chemical compound O([C@H](C)C(=O)N1CCOCC1)C(C=12)=CC=CC2=NC=NC=1NC(C=C1C)=CC=C1OC1=CN=CS1 AMBLTSYRYALCDZ-QGZVFWFLSA-N 0.000 claims description 2
• ORUUGJFPIMRJJV-GOSISDBHSA-N (2r)-2-[4-[3-methyl-4-(1-methylpyrazol-4-yl)oxyanilino]quinazolin-5-yl]oxy-1-morpholin-4-ylpropan-1-one Chemical compound O([C@H](C)C(=O)N1CCOCC1)C(C=12)=CC=CC2=NC=NC=1NC(C=C1C)=CC=C1OC=1C=NN(C)C=1 ORUUGJFPIMRJJV-GOSISDBHSA-N 0.000 claims description 2
• OPNCWWJMTAZREJ-OAQYLSRUSA-N (2r)-2-[4-[3-methyl-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-5-yl]oxy-1-(4-methylpiperazin-1-yl)propan-1-one Chemical compound O([C@H](C)C(=O)N1CCN(C)CC1)C(C=12)=CC=CC2=NC=NC=1NC(C=C1C)=CC=C1OC1=CC=C(C)N=C1 OPNCWWJMTAZREJ-OAQYLSRUSA-N 0.000 claims description 2
• SHUGRJASNGVPQD-HXUWFJFHSA-N (2r)-2-[4-[3-methyl-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-5-yl]oxy-1-morpholin-4-ylpropan-1-one Chemical compound O([C@H](C)C(=O)N1CCOCC1)C(C=12)=CC=CC2=NC=NC=1NC(C=C1C)=CC=C1OC1=CC=C(C)N=C1 SHUGRJASNGVPQD-HXUWFJFHSA-N 0.000 claims description 2
• ZYLSCLXBHVKVII-HXUWFJFHSA-N (2r)-2-[4-[3-methyl-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-5-yl]oxy-1-piperazin-1-ylpropan-1-one Chemical compound O([C@H](C)C(=O)N1CCNCC1)C(C=12)=CC=CC2=NC=NC=1NC(C=C1C)=CC=C1OC1=CC=C(C)N=C1 ZYLSCLXBHVKVII-HXUWFJFHSA-N 0.000 claims description 2
• KCYROHOXZDSAHS-MRXNPFEDSA-N (2r)-2-[4-[3-methyl-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-5-yl]oxypropanamide Chemical compound C=12C(O[C@H](C)C(N)=O)=CC=CC2=NC=NC=1NC(C=C1C)=CC=C1OC1=CC=C(C)N=C1 KCYROHOXZDSAHS-MRXNPFEDSA-N 0.000 claims description 2
• LJZISAWYNKRWIO-HXUWFJFHSA-N (2r)-2-[4-[3-methyl-4-(pyridin-2-ylmethoxy)anilino]quinazolin-5-yl]oxy-1-pyrrolidin-1-ylpropan-1-one Chemical compound O([C@H](C)C(=O)N1CCCC1)C(C=12)=CC=CC2=NC=NC=1NC(C=C1C)=CC=C1OCC1=CC=CC=N1 LJZISAWYNKRWIO-HXUWFJFHSA-N 0.000 claims description 2
• QFLYTKONAPWVDG-GOSISDBHSA-N (2r)-2-[4-[4-(6-fluoropyridin-3-yl)oxy-3-methylanilino]quinazolin-5-yl]oxy-1-morpholin-4-ylpropan-1-one Chemical compound O([C@H](C)C(=O)N1CCOCC1)C(C=12)=CC=CC2=NC=NC=1NC(C=C1C)=CC=C1OC1=CC=C(F)N=C1 QFLYTKONAPWVDG-GOSISDBHSA-N 0.000 claims description 2
• YJBCUEJJNJKFEU-LJQANCHMSA-N (2r)-2-[4-[4-(6-methoxypyridin-3-yl)oxy-3-methylanilino]quinazolin-5-yl]oxy-1-morpholin-4-ylpropan-1-one Chemical compound C1=NC(OC)=CC=C1OC(C(=C1)C)=CC=C1NC1=NC=NC2=CC=CC(O[C@H](C)C(=O)N3CCOCC3)=C12 YJBCUEJJNJKFEU-LJQANCHMSA-N 0.000 claims description 2
• GKIPTIQEDVKHHB-LJQANCHMSA-N (2r)-2-[4-[4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-5-yl]oxy-1-morpholin-4-ylpropan-1-one Chemical compound O([C@H](C)C(=O)N1CCOCC1)C(C=12)=CC=CC2=NC=NC=1NC(C=C1)=CC=C1OC1=CC=C(C)N=C1 GKIPTIQEDVKHHB-LJQANCHMSA-N 0.000 claims description 2
• PCBSKIFMBDGJTQ-LJQANCHMSA-N (2r)-2-[4-[4-[6-(fluoromethyl)pyridin-3-yl]oxy-3-methylanilino]quinazolin-5-yl]oxy-1-morpholin-4-ylpropan-1-one Chemical compound O([C@H](C)C(=O)N1CCOCC1)C(C=12)=CC=CC2=NC=NC=1NC(C=C1C)=CC=C1OC1=CC=C(CF)N=C1 PCBSKIFMBDGJTQ-LJQANCHMSA-N 0.000 claims description 2
• MKPQIRLXEPRMTF-LJQANCHMSA-N (2r)-2-[4-[4-[6-(hydroxymethyl)pyridin-3-yl]oxy-3-methylanilino]quinazolin-5-yl]oxy-1-morpholin-4-ylpropan-1-one Chemical compound O([C@H](C)C(=O)N1CCOCC1)C(C=12)=CC=CC2=NC=NC=1NC(C=C1C)=CC=C1OC1=CC=C(CO)N=C1 MKPQIRLXEPRMTF-LJQANCHMSA-N 0.000 claims description 2
• RZTBEOJPWQNXQS-HXUWFJFHSA-N (2r)-n,n-diethyl-2-[4-[3-methyl-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-5-yl]oxypropanamide Chemical compound C=12C(O[C@H](C)C(=O)N(CC)CC)=CC=CC2=NC=NC=1NC(C=C1C)=CC=C1OC1=CC=C(C)N=C1 RZTBEOJPWQNXQS-HXUWFJFHSA-N 0.000 claims description 2
• XNXUDGXKTVZKLB-GOSISDBHSA-N (2r)-n,n-dimethyl-2-[4-[3-methyl-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-5-yl]oxypropanamide Chemical compound C=12C(O[C@H](C)C(=O)N(C)C)=CC=CC2=NC=NC=1NC(C=C1C)=CC=C1OC1=CC=C(C)N=C1 XNXUDGXKTVZKLB-GOSISDBHSA-N 0.000 claims description 2
• FRIZWTSUZGRCOM-GOSISDBHSA-N (2r)-n-(2-hydroxyethyl)-2-[4-[3-methoxy-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-5-yl]oxy-n-methylpropanamide Chemical compound COC1=CC(NC=2C3=C(O[C@H](C)C(=O)N(C)CCO)C=CC=C3N=CN=2)=CC=C1OC1=CC=C(C)N=C1 FRIZWTSUZGRCOM-GOSISDBHSA-N 0.000 claims description 2
• AEOJOWVJRRLUDH-GOSISDBHSA-N (2r)-n-(2-hydroxyethyl)-n-methyl-2-[4-(3-methyl-4-pyridin-2-yloxyanilino)quinazolin-5-yl]oxypropanamide Chemical compound C=12C(O[C@H](C)C(=O)N(C)CCO)=CC=CC2=NC=NC=1NC(C=C1C)=CC=C1OC1=CC=CC=N1 AEOJOWVJRRLUDH-GOSISDBHSA-N 0.000 claims description 2
• RHKOFLSVENLYDP-LJQANCHMSA-N (2r)-n-(2-hydroxyethyl)-n-methyl-2-[4-[3-methyl-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-5-yl]oxypropanamide Chemical compound C=12C(O[C@H](C)C(=O)N(C)CCO)=CC=CC2=NC=NC=1NC(C=C1C)=CC=C1OC1=CC=C(C)N=C1 RHKOFLSVENLYDP-LJQANCHMSA-N 0.000 claims description 2
• FALHGGCCRVONDY-LJQANCHMSA-N (2r)-n-(2-hydroxyethyl)-n-methyl-2-[4-[3-methyl-4-(pyridin-2-ylmethoxy)anilino]quinazolin-5-yl]oxypropanamide Chemical compound C=12C(O[C@H](C)C(=O)N(C)CCO)=CC=CC2=NC=NC=1NC(C=C1C)=CC=C1OCC1=CC=CC=N1 FALHGGCCRVONDY-LJQANCHMSA-N 0.000 claims description 2
• ZEQVZRKILUBAEF-LJQANCHMSA-N (2r)-n-(2-methoxyethyl)-2-[4-[3-methoxy-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-5-yl]oxy-n-methylpropanamide Chemical compound C=12C(O[C@H](C)C(=O)N(C)CCOC)=CC=CC2=NC=NC=1NC(C=C1OC)=CC=C1OC1=CC=C(C)N=C1 ZEQVZRKILUBAEF-LJQANCHMSA-N 0.000 claims description 2
• SNIBNOLMGURVKM-HXUWFJFHSA-N (2r)-n-(2-methoxyethyl)-n-methyl-2-[4-[3-methyl-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-5-yl]oxypropanamide Chemical compound C=12C(O[C@H](C)C(=O)N(C)CCOC)=CC=CC2=NC=NC=1NC(C=C1C)=CC=C1OC1=CC=C(C)N=C1 SNIBNOLMGURVKM-HXUWFJFHSA-N 0.000 claims description 2
• XOPDMYXFRHOXFS-HXUWFJFHSA-N (2r)-n-(3-hydroxypropyl)-n-methyl-2-[4-[3-methyl-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-5-yl]oxypropanamide Chemical compound C=12C(O[C@H](C)C(=O)N(C)CCCO)=CC=CC2=NC=NC=1NC(C=C1C)=CC=C1OC1=CC=C(C)N=C1 XOPDMYXFRHOXFS-HXUWFJFHSA-N 0.000 claims description 2
• LJVILAHBLHROHD-QGZVFWFLSA-N (2r)-n-methyl-2-[4-[3-methyl-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-5-yl]oxypropanamide Chemical compound C=12C(O[C@H](C)C(=O)NC)=CC=CC2=NC=NC=1NC(C=C1C)=CC=C1OC1=CC=C(C)N=C1 LJVILAHBLHROHD-QGZVFWFLSA-N 0.000 claims description 2
• QSDGLFJIKRMVDL-QGZVFWFLSA-N (2r)-n-methyl-2-[4-[3-methyl-4-(pyridin-2-ylmethoxy)anilino]quinazolin-5-yl]oxypropanamide Chemical compound C=12C(O[C@H](C)C(=O)NC)=CC=CC2=NC=NC=1NC(C=C1C)=CC=C1OCC1=CC=CC=N1 QSDGLFJIKRMVDL-QGZVFWFLSA-N 0.000 claims description 2
• CUXVZRKCEYEHCD-FPOVZHCZSA-N (2s)-1-[(3s)-3-hydroxypyrrolidin-1-yl]-2-[4-[3-methyl-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-5-yl]oxypropan-1-one Chemical compound O([C@@H](C)C(=O)N1C[C@@H](O)CC1)C(C=12)=CC=CC2=NC=NC=1NC(C=C1C)=CC=C1OC1=CC=C(C)N=C1 CUXVZRKCEYEHCD-FPOVZHCZSA-N 0.000 claims description 2
• QPPYSOHWFOUKPX-INIZCTEOSA-N (2s)-2-[4-[3-chloro-4-(pyridin-2-ylmethoxy)anilino]quinazolin-5-yl]oxy-n,n-dimethylpropanamide Chemical compound C=12C(O[C@@H](C)C(=O)N(C)C)=CC=CC2=NC=NC=1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 QPPYSOHWFOUKPX-INIZCTEOSA-N 0.000 claims description 2
• WZEUNGUUUBFSGF-KRWDZBQOSA-N (2s)-2-[4-[3-chloro-4-(pyridin-2-ylmethoxy)anilino]quinazolin-5-yl]oxy-n-(2-hydroxyethyl)-n-methylpropanamide Chemical compound C=12C(O[C@@H](C)C(=O)N(C)CCO)=CC=CC2=NC=NC=1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 WZEUNGUUUBFSGF-KRWDZBQOSA-N 0.000 claims description 2
• QCTACFWJSRSNOJ-HNNXBMFYSA-N (2s)-2-[4-[3-chloro-4-(pyridin-2-ylmethoxy)anilino]quinazolin-5-yl]oxy-n-methylpropanamide Chemical compound C=12C(O[C@@H](C)C(=O)NC)=CC=CC2=NC=NC=1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 QCTACFWJSRSNOJ-HNNXBMFYSA-N 0.000 claims description 2
• DMWWQRAYTXZZJP-AWEZNQCLSA-N (2s)-2-[4-[3-chloro-4-(pyridin-2-ylmethoxy)anilino]quinazolin-5-yl]oxypropanamide Chemical compound C=12C(O[C@@H](C)C(N)=O)=CC=CC2=NC=NC=1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 DMWWQRAYTXZZJP-AWEZNQCLSA-N 0.000 claims description 2
• KCYROHOXZDSAHS-INIZCTEOSA-N (2s)-2-[4-[3-methyl-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-5-yl]oxypropanamide Chemical compound C=12C(O[C@@H](C)C(N)=O)=CC=CC2=NC=NC=1NC(C=C1C)=CC=C1OC1=CC=C(C)N=C1 KCYROHOXZDSAHS-INIZCTEOSA-N 0.000 claims description 2
• XNXUDGXKTVZKLB-SFHVURJKSA-N (2s)-n,n-dimethyl-2-[4-[3-methyl-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-5-yl]oxypropanamide Chemical compound C=12C(O[C@@H](C)C(=O)N(C)C)=CC=CC2=NC=NC=1NC(C=C1C)=CC=C1OC1=CC=C(C)N=C1 XNXUDGXKTVZKLB-SFHVURJKSA-N 0.000 claims description 2
• RHKOFLSVENLYDP-IBGZPJMESA-N (2s)-n-(2-hydroxyethyl)-n-methyl-2-[4-[3-methyl-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-5-yl]oxypropanamide Chemical compound C=12C(O[C@@H](C)C(=O)N(C)CCO)=CC=CC2=NC=NC=1NC(C=C1C)=CC=C1OC1=CC=C(C)N=C1 RHKOFLSVENLYDP-IBGZPJMESA-N 0.000 claims description 2
• LJVILAHBLHROHD-KRWDZBQOSA-N (2s)-n-methyl-2-[4-[3-methyl-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-5-yl]oxypropanamide Chemical compound C=12C(O[C@@H](C)C(=O)NC)=CC=CC2=NC=NC=1NC(C=C1C)=CC=C1OC1=CC=C(C)N=C1 LJVILAHBLHROHD-KRWDZBQOSA-N 0.000 claims description 2
• IQNBHURYIWAEOA-UHFFFAOYSA-N 2-[4-[3-chloro-4-(pyridin-2-ylmethoxy)anilino]quinazolin-5-yl]oxy-1-(4-methylpiperazin-1-yl)ethanone Chemical compound C1CN(C)CCN1C(=O)COC1=CC=CC2=NC=NC(NC=3C=C(Cl)C(OCC=4N=CC=CC=4)=CC=3)=C12 IQNBHURYIWAEOA-UHFFFAOYSA-N 0.000 claims description 2
• ABIIALBXPJPBAM-HXUWFJFHSA-N 2-[4-[3-chloro-4-(pyridin-2-ylmethoxy)anilino]quinazolin-5-yl]oxy-1-[(3r)-3-hydroxypyrrolidin-1-yl]-2-methylpropan-1-one Chemical compound C([C@H](O)CC1)N1C(=O)C(C)(C)OC(C=12)=CC=CC2=NC=NC=1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 ABIIALBXPJPBAM-HXUWFJFHSA-N 0.000 claims description 2
• IIDKWOQWPGRLIW-UHFFFAOYSA-N 2-[4-[3-chloro-4-(pyridin-2-ylmethoxy)anilino]quinazolin-5-yl]oxy-1-morpholin-4-ylethanone Chemical compound C=1C=C(OCC=2N=CC=CC=2)C(Cl)=CC=1NC(C=12)=NC=NC2=CC=CC=1OCC(=O)N1CCOCC1 IIDKWOQWPGRLIW-UHFFFAOYSA-N 0.000 claims description 2
• IOSVSLOBJIGVKD-UHFFFAOYSA-N 2-[4-[3-chloro-4-(pyridin-2-ylmethoxy)anilino]quinazolin-5-yl]oxy-1-piperazin-1-ylethanone Chemical compound C=1C=C(OCC=2N=CC=CC=2)C(Cl)=CC=1NC(C=12)=NC=NC2=CC=CC=1OCC(=O)N1CCNCC1 IOSVSLOBJIGVKD-UHFFFAOYSA-N 0.000 claims description 2
• ZTDGISKEIHFQJM-UHFFFAOYSA-N 2-[4-[3-chloro-4-(pyridin-2-ylmethoxy)anilino]quinazolin-5-yl]oxy-2-methylpropanamide Chemical compound C=12C(OC(C)(C)C(N)=O)=CC=CC2=NC=NC=1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 ZTDGISKEIHFQJM-UHFFFAOYSA-N 0.000 claims description 2
• UUJIQLYAPKAFLJ-UHFFFAOYSA-N 2-[4-[3-chloro-4-(pyridin-2-ylmethoxy)anilino]quinazolin-5-yl]oxy-n,2-dimethylpropanamide Chemical compound C=12C(OC(C)(C)C(=O)NC)=CC=CC2=NC=NC=1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 UUJIQLYAPKAFLJ-UHFFFAOYSA-N 0.000 claims description 2
• WNSZUBQSBHVHRR-UHFFFAOYSA-N 2-[4-[3-chloro-4-(pyridin-2-ylmethoxy)anilino]quinazolin-5-yl]oxy-n,n-bis(2-hydroxyethyl)-2-methylpropanamide Chemical compound C=12C(OC(C)(C)C(=O)N(CCO)CCO)=CC=CC2=NC=NC=1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 WNSZUBQSBHVHRR-UHFFFAOYSA-N 0.000 claims description 2
• PMYRQDIKMXVAIG-UHFFFAOYSA-N 2-[4-[3-chloro-4-(pyridin-2-ylmethoxy)anilino]quinazolin-5-yl]oxy-n-(1-hydroxy-2-methylpropan-2-yl)-2-methylpropanamide Chemical compound C=12C(OC(C)(C)C(=O)NC(C)(CO)C)=CC=CC2=NC=NC=1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 PMYRQDIKMXVAIG-UHFFFAOYSA-N 0.000 claims description 2
• INQQFMUBAXLUJS-UHFFFAOYSA-N 2-[4-[3-chloro-4-(pyridin-2-ylmethoxy)anilino]quinazolin-5-yl]oxy-n-(2-hydroxyethyl)-n,2-dimethylpropanamide Chemical compound C=12C(OC(C)(C)C(=O)N(CCO)C)=CC=CC2=NC=NC=1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 INQQFMUBAXLUJS-UHFFFAOYSA-N 0.000 claims description 2
• DQSMJIPNCYLKDQ-UHFFFAOYSA-N 2-[4-[3-chloro-4-(pyridin-2-ylmethoxy)anilino]quinazolin-5-yl]oxy-n-(2-hydroxyethyl)-n-methylacetamide Chemical class C=12C(OCC(=O)N(CCO)C)=CC=CC2=NC=NC=1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 DQSMJIPNCYLKDQ-UHFFFAOYSA-N 0.000 claims description 2
• GAIHXYHHTKIHDB-UHFFFAOYSA-N 2-[4-[3-chloro-4-(pyridin-2-ylmethoxy)anilino]quinazolin-5-yl]oxy-n-(2-methoxyethyl)acetamide Chemical compound C=12C(OCC(=O)NCCOC)=CC=CC2=NC=NC=1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 GAIHXYHHTKIHDB-UHFFFAOYSA-N 0.000 claims description 2
• HXVZBSLWEFSIDC-UHFFFAOYSA-N 2-[4-[3-chloro-4-(pyridin-2-ylmethoxy)anilino]quinazolin-5-yl]oxy-n-(2-methylsulfonylethyl)acetamide Chemical compound C=12C(OCC(=O)NCCS(=O)(=O)C)=CC=CC2=NC=NC=1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 HXVZBSLWEFSIDC-UHFFFAOYSA-N 0.000 claims description 2
• ZHJQWJWANKXJCA-UHFFFAOYSA-N 2-[4-[3-chloro-4-(pyridin-2-ylmethoxy)anilino]quinazolin-5-yl]oxy-n-[2-(dimethylamino)ethyl]-n-methylacetamide Chemical class C=12C(OCC(=O)N(C)CCN(C)C)=CC=CC2=NC=NC=1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 ZHJQWJWANKXJCA-UHFFFAOYSA-N 0.000 claims description 2
• HNILLTAIVGZWKT-UHFFFAOYSA-N 2-[4-[3-chloro-4-(pyridin-2-ylmethoxy)anilino]quinazolin-5-yl]oxy-n-cyclobutylacetamide Chemical compound C=1C=C(OCC=2N=CC=CC=2)C(Cl)=CC=1NC(C=12)=NC=NC2=CC=CC=1OCC(=O)NC1CCC1 HNILLTAIVGZWKT-UHFFFAOYSA-N 0.000 claims description 2
• QVFTYRILTKIJRJ-UHFFFAOYSA-N 2-[4-[3-chloro-4-(pyridin-2-ylmethoxy)anilino]quinazolin-5-yl]oxy-n-cyclopropylacetamide Chemical compound C=1C=C(OCC=2N=CC=CC=2)C(Cl)=CC=1NC(C=12)=NC=NC2=CC=CC=1OCC(=O)NC1CC1 QVFTYRILTKIJRJ-UHFFFAOYSA-N 0.000 claims description 2
• DHBDAUZNAMLHQZ-UHFFFAOYSA-N 2-[4-[3-chloro-4-(pyridin-2-ylmethoxy)anilino]quinazolin-5-yl]oxy-n-ethyl-n-methylacetamide Chemical compound C=12C(OCC(=O)N(C)CC)=CC=CC2=NC=NC=1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 DHBDAUZNAMLHQZ-UHFFFAOYSA-N 0.000 claims description 2
• XTDATAMURAGLJB-UHFFFAOYSA-N 2-[4-[3-chloro-4-(pyridin-2-ylmethoxy)anilino]quinazolin-5-yl]oxy-n-ethylacetamide Chemical compound C=12C(OCC(=O)NCC)=CC=CC2=NC=NC=1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 XTDATAMURAGLJB-UHFFFAOYSA-N 0.000 claims description 2
• UPENTKJYYQBAOY-UHFFFAOYSA-N 2-[4-[3-chloro-4-(pyridin-2-ylmethoxy)anilino]quinazolin-5-yl]oxy-n-methyl-n-(1-methylpiperidin-4-yl)acetamide Chemical compound C=1C=CC2=NC=NC(NC=3C=C(Cl)C(OCC=4N=CC=CC=4)=CC=3)=C2C=1OCC(=O)N(C)C1CCN(C)CC1 UPENTKJYYQBAOY-UHFFFAOYSA-N 0.000 claims description 2
• OAOJKRWXBFFKPW-UHFFFAOYSA-N 2-[4-[3-chloro-4-(pyridin-2-ylmethoxy)anilino]quinazolin-5-yl]oxy-n-methyl-n-(2-methylsulfonylethyl)acetamide Chemical compound C=12C(OCC(=O)N(CCS(C)(=O)=O)C)=CC=CC2=NC=NC=1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 OAOJKRWXBFFKPW-UHFFFAOYSA-N 0.000 claims description 2
• YSVANPFEFQDDEF-UHFFFAOYSA-N 2-[4-[3-chloro-4-(pyridin-2-ylmethoxy)anilino]quinazolin-5-yl]oxy-n-methyl-n-prop-2-ynylacetamide Chemical compound C=12C(OCC(=O)N(CC#C)C)=CC=CC2=NC=NC=1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 YSVANPFEFQDDEF-UHFFFAOYSA-N 0.000 claims description 2
• KTKJBYIXTZKZHP-UHFFFAOYSA-N 2-[4-[3-chloro-4-(pyridin-2-ylmethoxy)anilino]quinazolin-5-yl]oxy-n-methyl-n-propan-2-ylacetamide Chemical compound C=12C(OCC(=O)N(C)C(C)C)=CC=CC2=NC=NC=1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 KTKJBYIXTZKZHP-UHFFFAOYSA-N 0.000 claims description 2
• DEDWEDQNCVGJQP-UHFFFAOYSA-N 2-[4-[3-chloro-4-(pyridin-2-ylmethoxy)anilino]quinazolin-5-yl]oxyacetamide Chemical compound C=12C(OCC(=O)N)=CC=CC2=NC=NC=1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 DEDWEDQNCVGJQP-UHFFFAOYSA-N 0.000 claims description 2
• PBTDMULPNDZNOI-UHFFFAOYSA-N 2-[4-[3-methyl-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-5-yl]oxy-1-(4-methylpiperazin-1-yl)ethanone Chemical compound C1CN(C)CCN1C(=O)COC1=CC=CC2=NC=NC(NC=3C=C(C)C(OC=4C=NC(C)=CC=4)=CC=3)=C12 PBTDMULPNDZNOI-UHFFFAOYSA-N 0.000 claims description 2
• DBBOWDJNLYCSHP-UHFFFAOYSA-N 2-[4-[3-methyl-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-5-yl]oxy-1-piperazin-1-ylethanone Chemical compound C1=NC(C)=CC=C1OC(C(=C1)C)=CC=C1NC1=NC=NC2=CC=CC(OCC(=O)N3CCNCC3)=C12 DBBOWDJNLYCSHP-UHFFFAOYSA-N 0.000 claims description 2
• OQMPFANZXGBCKF-UHFFFAOYSA-N 2-[4-[3-methyl-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-5-yl]oxy-1-pyrrolidin-1-ylethanone Chemical compound C1=NC(C)=CC=C1OC(C(=C1)C)=CC=C1NC1=NC=NC2=CC=CC(OCC(=O)N3CCCC3)=C12 OQMPFANZXGBCKF-UHFFFAOYSA-N 0.000 claims description 2
• PXSWJYXXYJFXSI-UHFFFAOYSA-N 2-[4-[3-methyl-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-5-yl]oxyacetamide Chemical compound C1=NC(C)=CC=C1OC(C(=C1)C)=CC=C1NC1=NC=NC2=CC=CC(OCC(N)=O)=C12 PXSWJYXXYJFXSI-UHFFFAOYSA-N 0.000 claims description 2
• OVUYBBZPOKGMQD-UHFFFAOYSA-N 2-methyl-2-[4-[3-methyl-4-(pyridin-2-ylmethoxy)anilino]quinazolin-5-yl]oxypropanamide Chemical compound CC1=CC(NC=2C3=C(OC(C)(C)C(N)=O)C=CC=C3N=CN=2)=CC=C1OCC1=CC=CC=N1 OVUYBBZPOKGMQD-UHFFFAOYSA-N 0.000 claims description 2
• UBNGYIRTUXFYMI-MRXNPFEDSA-N 4-[(2r)-2-[4-(3-chloro-4-pyridin-2-yloxyanilino)quinazolin-5-yl]oxypropanoyl]piperazin-2-one Chemical compound O([C@H](C)C(=O)N1CC(=O)NCC1)C(C=12)=CC=CC2=NC=NC=1NC(C=C1Cl)=CC=C1OC1=CC=CC=N1 UBNGYIRTUXFYMI-MRXNPFEDSA-N 0.000 claims description 2
• MFGZYITYUFKFHM-GOSISDBHSA-N 4-[(2r)-2-[4-(3-methyl-4-pyridin-2-yloxyanilino)quinazolin-5-yl]oxypropanoyl]piperazin-2-one Chemical compound O([C@H](C)C(=O)N1CC(=O)NCC1)C(C=12)=CC=CC2=NC=NC=1NC(C=C1C)=CC=C1OC1=CC=CC=N1 MFGZYITYUFKFHM-GOSISDBHSA-N 0.000 claims description 2
• DVIMMYUPPSUXDO-LJQANCHMSA-N 4-[(2r)-2-[4-[3-methyl-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-5-yl]oxypropanoyl]piperazin-2-one Chemical compound O([C@H](C)C(=O)N1CC(=O)NCC1)C(C=12)=CC=CC2=NC=NC=1NC(C=C1C)=CC=C1OC1=CC=C(C)N=C1 DVIMMYUPPSUXDO-LJQANCHMSA-N 0.000 claims description 2
• HCGLYZMEYZJQJM-LJQANCHMSA-N 5-[2-methyl-4-[[5-[(2r)-1-morpholin-4-yl-1-oxopropan-2-yl]oxyquinazolin-4-yl]amino]phenoxy]pyridine-2-carbonitrile Chemical compound O([C@H](C)C(=O)N1CCOCC1)C(C=12)=CC=CC2=NC=NC=1NC(C=C1C)=CC=C1OC1=CC=C(C#N)N=C1 HCGLYZMEYZJQJM-LJQANCHMSA-N 0.000 claims description 2
• PGZANCNVVXOVQP-GOSISDBHSA-N 5-[[5-[(2r)-1-morpholin-4-yl-1-oxopropan-2-yl]oxyquinazolin-4-yl]amino]-2-pyridin-3-yloxybenzonitrile Chemical compound O([C@H](C)C(=O)N1CCOCC1)C(C=12)=CC=CC2=NC=NC=1NC(C=C1C#N)=CC=C1OC1=CC=CN=C1 PGZANCNVVXOVQP-GOSISDBHSA-N 0.000 claims description 2
• KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 2
• 125000004744 butyloxycarbonyl group Chemical group 0.000 claims description 2
• RXBOEADRGWCNCJ-UHFFFAOYSA-N n-(2-hydroxyethyl)-2-[4-[3-methyl-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-5-yl]oxyacetamide Chemical compound C1=NC(C)=CC=C1OC(C(=C1)C)=CC=C1NC1=NC=NC2=CC=CC(OCC(=O)NCCO)=C12 RXBOEADRGWCNCJ-UHFFFAOYSA-N 0.000 claims description 2
• NOMRZODRIRQWID-UHFFFAOYSA-N n-methyl-2-[4-[3-methyl-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-5-yl]oxyacetamide Chemical compound C=12C(OCC(=O)NC)=CC=CC2=NC=NC=1NC(C=C1C)=CC=C1OC1=CC=C(C)N=C1 NOMRZODRIRQWID-UHFFFAOYSA-N 0.000 claims description 2
• 125000005740 oxycarbonyl group Chemical group [*:1]OC([*:2])=O 0.000 claims description 2
• IWELDVXSEVIIGI-UHFFFAOYSA-N piperazin-2-one Chemical compound O=C1CNCCN1 IWELDVXSEVIIGI-UHFFFAOYSA-N 0.000 claims description 2
• OTPMITWGYZDQSV-HSZRJFAPSA-N tert-butyl 4-[(2r)-2-[4-[3-methyl-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-5-yl]oxypropanoyl]piperazine-1-carboxylate Chemical compound O([C@H](C)C(=O)N1CCN(CC1)C(=O)OC(C)(C)C)C(C=12)=CC=CC2=NC=NC=1NC(C=C1C)=CC=C1OC1=CC=C(C)N=C1 OTPMITWGYZDQSV-HSZRJFAPSA-N 0.000 claims description 2
• DLFVBJFMPXGRIB-UHFFFAOYSA-N thioacetamide Natural products CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims description 2
• 150000003246 quinazolines Chemical class 0.000 claims 26
• UUEVFMOUBSLVJW-UHFFFAOYSA-N oxo-[[1-[2-[2-[2-[4-(oxoazaniumylmethylidene)pyridin-1-yl]ethoxy]ethoxy]ethyl]pyridin-4-ylidene]methyl]azanium;dibromide Chemical compound [Br-].[Br-].C1=CC(=C[NH+]=O)C=CN1CCOCCOCCN1C=CC(=C[NH+]=O)C=C1 UUEVFMOUBSLVJW-UHFFFAOYSA-N 0.000 claims 2
• XSSFNNOZFIXWDF-GOSISDBHSA-N (2r)-2-[4-[3-fluoro-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-5-yl]oxy-1-morpholin-4-ylpropan-1-one Chemical compound O([C@H](C)C(=O)N1CCOCC1)C(C=12)=CC=CC2=NC=NC=1NC(C=C1F)=CC=C1OC1=CC=C(C)N=C1 XSSFNNOZFIXWDF-GOSISDBHSA-N 0.000 claims 1
• AXAMEWIVQQBQPF-LJQANCHMSA-N (2r)-2-[4-[3-methoxy-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-5-yl]oxy-1-piperazin-1-ylpropan-1-one Chemical compound O=C([C@@H](C)OC=1C=CC=C2N=CN=C(C=12)NC=1C=C(C(=CC=1)OC=1C=NC(C)=CC=1)OC)N1CCNCC1 AXAMEWIVQQBQPF-LJQANCHMSA-N 0.000 claims 1
• 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 claims 1
• 239000003085 diluting agent Substances 0.000 claims 1
• 125000000446 sulfanediyl group Chemical group *S* 0.000 claims 1
• 125000005301 thienylmethyl group Chemical group [H]C1=C([H])C([H])=C(S1)C([H])([H])* 0.000 claims 1
• 206010028980 Neoplasm Diseases 0.000 abstract description 30
• 230000005764 inhibitory process Effects 0.000 abstract description 18
• 238000011282 treatment Methods 0.000 abstract description 14
• 102000001301 EGF receptor Human genes 0.000 abstract description 12
• 108060006698 EGF receptor Proteins 0.000 abstract description 12
• 238000002360 preparation method Methods 0.000 abstract description 6
• 239000003795 chemical substances by application Substances 0.000 abstract description 4
• 230000002265 prevention Effects 0.000 abstract description 2
• 229960005419 nitrogen Drugs 0.000 description 66
• 210000004027 cell Anatomy 0.000 description 55
• 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 34
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 28
• 239000002585 base Substances 0.000 description 25
• QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 25
• 238000012360 testing method Methods 0.000 description 25
• YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 24
• ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 24
• YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 24
• 230000000694 effects Effects 0.000 description 23
• WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 20
• LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 20
• 239000002953 phosphate buffered saline Substances 0.000 description 20
• 239000000243 solution Substances 0.000 description 20
• KPCZJLGGXRGYIE-UHFFFAOYSA-N [C]1=CC=CN=C1 Chemical group [C]1=CC=CN=C1 KPCZJLGGXRGYIE-UHFFFAOYSA-N 0.000 description 19
• 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 19
• 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 19
• YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 19
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
• VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 18
• XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 15
• SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 15
• 239000002253 acid Substances 0.000 description 15
• 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 15
• 201000011510 cancer Diseases 0.000 description 15
• 150000001721 carbon Chemical group 0.000 description 15
• 230000026731 phosphorylation Effects 0.000 description 15
• 238000006366 phosphorylation reaction Methods 0.000 description 15
• 239000007858 starting material Substances 0.000 description 15
• HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 14
• 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 14
• 229910052784 alkaline earth metal Inorganic materials 0.000 description 13
• 239000012442 inert solvent Substances 0.000 description 13
• 102000027426 receptor tyrosine kinases Human genes 0.000 description 12
• 108091008598 receptor tyrosine kinases Proteins 0.000 description 12
• 239000003701 inert diluent Substances 0.000 description 11
• 102000005962 receptors Human genes 0.000 description 11
• 108020003175 receptors Proteins 0.000 description 11
• RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 10
• QMNUDYFKZYBWQX-UHFFFAOYSA-N 1H-quinazolin-4-one Chemical compound C1=CC=C2C(=O)N=CNC2=C1 QMNUDYFKZYBWQX-UHFFFAOYSA-N 0.000 description 10
• 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 10
• 238000003556 assay Methods 0.000 description 10
• 239000003112 inhibitor Substances 0.000 description 10
• BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 10
• 239000002904 solvent Substances 0.000 description 10
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
• 238000007796 conventional method Methods 0.000 description 9
• 150000002170 ethers Chemical class 0.000 description 9
• 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 9
• 125000002950 monocyclic group Chemical group 0.000 description 9
• YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 9
• 210000004881 tumor cell Anatomy 0.000 description 9
• VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 8
• FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 8
• CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 8
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
• 239000003849 aromatic solvent Substances 0.000 description 8
• 150000002148 esters Chemical class 0.000 description 8
• 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 8
• 125000002883 imidazolyl group Chemical group 0.000 description 8
• 125000000842 isoxazolyl group Chemical group 0.000 description 8
• 239000000203 mixture Substances 0.000 description 8
• 230000035755 proliferation Effects 0.000 description 8
• RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 8
• 241000699670 Mus sp. Species 0.000 description 7
• 108700020796 Oncogene Proteins 0.000 description 7
• 108091000080 Phosphotransferase Proteins 0.000 description 7
• 239000000010 aprotic solvent Substances 0.000 description 7
• ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 7
• 238000011534 incubation Methods 0.000 description 7
• 208000002154 non-small cell lung carcinoma Diseases 0.000 description 7
• 102000020233 phosphotransferase Human genes 0.000 description 7
• 102000004169 proteins and genes Human genes 0.000 description 7
• 108090000623 proteins and genes Proteins 0.000 description 7
• 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 7
• OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-dimethylpyridine Chemical compound CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 6
• JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 6
• RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
• SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 6
• KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
• 150000001298 alcohols Chemical class 0.000 description 6
• 239000003513 alkali Substances 0.000 description 6
• 238000004458 analytical method Methods 0.000 description 6
• 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 6
• XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 6
• 239000000543 intermediate Substances 0.000 description 6
• 230000035772 mutation Effects 0.000 description 6
• MTSNDBYBIZSILH-UHFFFAOYSA-N n-phenylquinazolin-4-amine Chemical group N=1C=NC2=CC=CC=C2C=1NC1=CC=CC=C1 MTSNDBYBIZSILH-UHFFFAOYSA-N 0.000 description 6
• 229920000136 polysorbate Polymers 0.000 description 6
• 108090000765 processed proteins & peptides Proteins 0.000 description 6
• VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 6
• ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 5
• ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 5
• PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical group NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 5
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
• 102400001368 Epidermal growth factor Human genes 0.000 description 5
• 101800003838 Epidermal growth factor Proteins 0.000 description 5
• 239000007995 HEPES buffer Substances 0.000 description 5
• 108010001336 Horseradish Peroxidase Proteins 0.000 description 5
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
• 239000005411 L01XE02 - Gefitinib Substances 0.000 description 5
• KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 5
• 229910052783 alkali metal Inorganic materials 0.000 description 5
• 229940116977 epidermal growth factor Drugs 0.000 description 5
• 239000003797 essential amino acid Substances 0.000 description 5
• 235000020776 essential amino acid Nutrition 0.000 description 5
• 229960002584 gefitinib Drugs 0.000 description 5
• BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Natural products O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 5
• 239000001963 growth medium Substances 0.000 description 5
• 230000003834 intracellular effect Effects 0.000 description 5
• 125000002757 morpholinyl group Chemical group 0.000 description 5
• 125000004193 piperazinyl group Chemical group 0.000 description 5
• 229910000027 potassium carbonate Inorganic materials 0.000 description 5
• 235000018102 proteins Nutrition 0.000 description 5
• 125000004307 pyrazin-2-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 description 5
• 125000002206 pyridazin-3-yl group Chemical group [H]C1=C([H])C([H])=C(*)N=N1 0.000 description 5
• 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 description 5
• 239000012312 sodium hydride Substances 0.000 description 5
• 229910000104 sodium hydride Inorganic materials 0.000 description 5
• 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 5
• 125000004793 2,2,2-trifluoroethoxy group Chemical group FC(CO*)(F)F 0.000 description 4
• VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
• 125000002373 5 membered heterocyclic group Chemical group 0.000 description 4
• 125000004070 6 membered heterocyclic group Chemical group 0.000 description 4
• JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
• WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 4
• DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
• 229910000102 alkali metal hydride Inorganic materials 0.000 description 4
• 150000008046 alkali metal hydrides Chemical class 0.000 description 4
• 230000000259 anti-tumor effect Effects 0.000 description 4
• 210000003050 axon Anatomy 0.000 description 4
• 230000000903 blocking effect Effects 0.000 description 4
• 229910000019 calcium carbonate Inorganic materials 0.000 description 4
• 230000000875 corresponding effect Effects 0.000 description 4
• 125000004122 cyclic group Chemical group 0.000 description 4
• 238000011161 development Methods 0.000 description 4
• 230000018109 developmental process Effects 0.000 description 4
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
• AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 4
• 239000012091 fetal bovine serum Substances 0.000 description 4
• 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 4
• 239000003446 ligand Substances 0.000 description 4
• 125000005647 linker group Chemical group 0.000 description 4
• XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 4
• 230000003389 potentiating effect Effects 0.000 description 4
• 239000000376 reactant Substances 0.000 description 4
• 230000004044 response Effects 0.000 description 4
• 239000011734 sodium Substances 0.000 description 4
• 229910000029 sodium carbonate Inorganic materials 0.000 description 4
• 239000011780 sodium chloride Substances 0.000 description 4
• 230000004083 survival effect Effects 0.000 description 4
• 238000003786 synthesis reaction Methods 0.000 description 4
• 210000001519 tissue Anatomy 0.000 description 4
• 238000005406 washing Methods 0.000 description 4
• JPRPJUMQRZTTED-UHFFFAOYSA-N 1,3-dioxolanyl Chemical group [CH]1OCCO1 JPRPJUMQRZTTED-UHFFFAOYSA-N 0.000 description 3
• 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 3
• 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 3
• 208000026310 Breast neoplasm Diseases 0.000 description 3
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
• 239000005551 L01XE03 - Erlotinib Substances 0.000 description 3
• 238000006751 Mitsunobu reaction Methods 0.000 description 3
• JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 3
• 229920001213 Polysorbate 20 Polymers 0.000 description 3
• 102000004257 Potassium Channel Human genes 0.000 description 3
• 229920004890 Triton X-100 Polymers 0.000 description 3
• 239000013504 Triton X-100 Substances 0.000 description 3
• GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 3
• 102000004142 Trypsin Human genes 0.000 description 3
• 108090000631 Trypsin Proteins 0.000 description 3
• 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 3
• 238000007080 aromatic substitution reaction Methods 0.000 description 3
• 230000015572 biosynthetic process Effects 0.000 description 3
• FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 3
• 229910000024 caesium carbonate Inorganic materials 0.000 description 3
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
• 239000003054 catalyst Substances 0.000 description 3
• 210000000170 cell membrane Anatomy 0.000 description 3
• KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
• 238000010520 demethylation reaction Methods 0.000 description 3
• 201000010099 disease Diseases 0.000 description 3
• 230000002255 enzymatic effect Effects 0.000 description 3
• 238000001640 fractional crystallisation Methods 0.000 description 3
• OVEHNNQXLPJPPL-UHFFFAOYSA-N lithium;n-propan-2-ylpropan-2-amine Chemical compound [Li].CC(C)NC(C)C OVEHNNQXLPJPPL-UHFFFAOYSA-N 0.000 description 3
• 239000006166 lysate Substances 0.000 description 3
• 239000002609 medium Substances 0.000 description 3
• 230000004048 modification Effects 0.000 description 3
• 238000012986 modification Methods 0.000 description 3
• 102000037979 non-receptor tyrosine kinases Human genes 0.000 description 3
• 108091008046 non-receptor tyrosine kinases Proteins 0.000 description 3
• 230000002018 overexpression Effects 0.000 description 3
• 239000012071 phase Substances 0.000 description 3
• 150000003003 phosphines Chemical group 0.000 description 3
• 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
• 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
• 108020001213 potassium channel Proteins 0.000 description 3
• NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
• 102000004196 processed proteins & peptides Human genes 0.000 description 3
• 239000000047 product Substances 0.000 description 3
• 230000009822 protein phosphorylation Effects 0.000 description 3
• 125000003226 pyrazolyl group Chemical group 0.000 description 3
• 210000002966 serum Anatomy 0.000 description 3
• 230000019491 signal transduction Effects 0.000 description 3
• FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
• 239000000758 substrate Substances 0.000 description 3
• LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 3
• 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
• 125000000335 thiazolyl group Chemical group 0.000 description 3
• 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
• 239000012588 trypsin Substances 0.000 description 3
• OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
• 235000002374 tyrosine Nutrition 0.000 description 3
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
• 125000006274 (C1-C3)alkoxy group Chemical group 0.000 description 2
• 125000005940 1,4-dioxanyl group Chemical group 0.000 description 2
• LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 2
• SNUSZUYTMHKCPM-UHFFFAOYSA-N 1-hydroxypyridin-2-one Chemical compound ON1C=CC=CC1=O SNUSZUYTMHKCPM-UHFFFAOYSA-N 0.000 description 2
• 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 2
• 125000001340 2-chloroethyl group Chemical group [H]C([H])(Cl)C([H])([H])* 0.000 description 2
• 125000001731 2-cyanoethyl group Chemical group [H]C([H])(*)C([H])([H])C#N 0.000 description 2
• XWKFPIODWVPXLX-UHFFFAOYSA-N 2-methyl-5-methylpyridine Natural products CC1=CC=C(C)N=C1 XWKFPIODWVPXLX-UHFFFAOYSA-N 0.000 description 2
• 125000004485 2-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])C1([H])* 0.000 description 2
• AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 2
• FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 2
• 125000001963 4 membered heterocyclic group Chemical group 0.000 description 2
• 125000004217 4-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C([H])([H])* 0.000 description 2
• 125000004195 4-methylpiperazin-1-yl group Chemical group [H]C([H])([H])N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 2
• UXEZULVIMJVIFB-UHFFFAOYSA-N 5-fluoro-1h-quinazolin-4-one Chemical compound N1C=NC(=O)C2=C1C=CC=C2F UXEZULVIMJVIFB-UHFFFAOYSA-N 0.000 description 2
• HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Natural products CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
• 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 2
• UYIFTLBWAOGQBI-BZDYCCQFSA-N Benzhormovarine Chemical compound C([C@@H]1[C@@H](C2=CC=3)CC[C@]4([C@H]1CC[C@@H]4O)C)CC2=CC=3OC(=O)C1=CC=CC=C1 UYIFTLBWAOGQBI-BZDYCCQFSA-N 0.000 description 2
• 206010006187 Breast cancer Diseases 0.000 description 2
• 230000004544 DNA amplification Effects 0.000 description 2
• QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
• 102000004190 Enzymes Human genes 0.000 description 2
• 108090000790 Enzymes Proteins 0.000 description 2
• 239000007821 HATU Substances 0.000 description 2
• 241000282412 Homo Species 0.000 description 2
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
• BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
• YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
• ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
• BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 2
• NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
• 208000004403 Prostatic Hyperplasia Diseases 0.000 description 2
• 201000004681 Psoriasis Diseases 0.000 description 2
• 102000001332 SRC Human genes 0.000 description 2
• 108060006706 SRC Proteins 0.000 description 2
• 229940124639 Selective inhibitor Drugs 0.000 description 2
• 229910021607 Silver chloride Inorganic materials 0.000 description 2
• QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
• 230000002159 abnormal effect Effects 0.000 description 2
• 238000002835 absorbance Methods 0.000 description 2
• 125000002252 acyl group Chemical group 0.000 description 2
• 125000005092 alkenyloxycarbonyl group Chemical group 0.000 description 2
• VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 2
• 125000003368 amide group Chemical group 0.000 description 2
• 125000003277 amino group Chemical group 0.000 description 2
• 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 2
• HOPRXXXSABQWAV-UHFFFAOYSA-N anhydrous collidine Natural products CC1=CC=NC(C)=C1C HOPRXXXSABQWAV-UHFFFAOYSA-N 0.000 description 2
• CBHOOMGKXCMKIR-UHFFFAOYSA-N azane;methanol Chemical compound N.OC CBHOOMGKXCMKIR-UHFFFAOYSA-N 0.000 description 2
• 125000000649 benzylidene group Chemical group [H]C(=[*])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
• 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 2
• 125000002619 bicyclic group Chemical group 0.000 description 2
• ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 2
• 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 2
• 150000001718 carbodiimides Chemical class 0.000 description 2
• 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 2
• 230000003197 catalytic effect Effects 0.000 description 2
• 230000004663 cell proliferation Effects 0.000 description 2
• 238000001516 cell proliferation assay Methods 0.000 description 2
• 230000001413 cellular effect Effects 0.000 description 2
• 239000003610 charcoal Substances 0.000 description 2
• 239000003153 chemical reaction reagent Substances 0.000 description 2
• 239000003638 chemical reducing agent Substances 0.000 description 2
• 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 2
• UTBIMNXEDGNJFE-UHFFFAOYSA-N collidine Natural products CC1=CC=C(C)C(C)=N1 UTBIMNXEDGNJFE-UHFFFAOYSA-N 0.000 description 2
• 230000008878 coupling Effects 0.000 description 2
• 238000010168 coupling process Methods 0.000 description 2
• FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Substances CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 2
• 230000004069 differentiation Effects 0.000 description 2
• 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 description 2
• 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 2
• 229940121647 egfr inhibitor Drugs 0.000 description 2
• 229940088598 enzyme Drugs 0.000 description 2
• 229960001433 erlotinib Drugs 0.000 description 2
• 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 2
• 125000006534 ethyl amino methyl group Chemical group [H]N(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 description 2
• FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical compound CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 description 2
• DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 2
• 238000002474 experimental method Methods 0.000 description 2
• 230000014509 gene expression Effects 0.000 description 2
• 239000011521 glass Substances 0.000 description 2
• 229940093915 gynecological organic acid Drugs 0.000 description 2
• 230000002140 halogenating effect Effects 0.000 description 2
• 238000010438 heat treatment Methods 0.000 description 2
• 238000004128 high performance liquid chromatography Methods 0.000 description 2
• 230000007062 hydrolysis Effects 0.000 description 2
• 238000006460 hydrolysis reaction Methods 0.000 description 2
• 238000012744 immunostaining Methods 0.000 description 2
• 238000001727 in vivo Methods 0.000 description 2
• 125000001786 isothiazolyl group Chemical group 0.000 description 2
• 210000003734 kidney Anatomy 0.000 description 2
• 239000012139 lysis buffer Substances 0.000 description 2
• 230000003211 malignant effect Effects 0.000 description 2
• 238000005259 measurement Methods 0.000 description 2
• 230000001404 mediated effect Effects 0.000 description 2
• JQSVJGUNGQUEQH-CQSZACIVSA-N methyl (2r)-2-[4-(3-chloro-4-pyridin-2-yloxyanilino)quinazolin-5-yl]oxypropanoate Chemical compound C=12C(O[C@H](C)C(=O)OC)=CC=CC2=NC=NC=1NC(C=C1Cl)=CC=C1OC1=CC=CC=N1 JQSVJGUNGQUEQH-CQSZACIVSA-N 0.000 description 2
• 125000006533 methyl amino methyl group Chemical group [H]N(C([H])([H])[H])C([H])([H])* 0.000 description 2
• 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 2
• 150000007522 mineralic acids Chemical class 0.000 description 2
• 230000027405 negative regulation of phosphorylation Effects 0.000 description 2
• 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
• 150000007524 organic acids Chemical class 0.000 description 2
• 235000005985 organic acids Nutrition 0.000 description 2
• 230000003204 osmotic effect Effects 0.000 description 2
• 125000002971 oxazolyl group Chemical group 0.000 description 2
• 125000003551 oxepanyl group Chemical group 0.000 description 2
• 125000003566 oxetanyl group Chemical group 0.000 description 2
• 125000004430 oxygen atom Chemical group O* 0.000 description 2
• 230000000144 pharmacologic effect Effects 0.000 description 2
• 229960003531 phenolsulfonphthalein Drugs 0.000 description 2
• YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
• UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 2
• 230000000704 physical effect Effects 0.000 description 2
• 230000002062 proliferating effect Effects 0.000 description 2
• 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 2
• 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 2
• UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
• 230000009467 reduction Effects 0.000 description 2
• 230000001105 regulatory effect Effects 0.000 description 2
• 238000011160 research Methods 0.000 description 2
• 239000012679 serum free medium Substances 0.000 description 2
• SCPYDCQAZCOKTP-UHFFFAOYSA-N silanol Chemical compound [SiH3]O SCPYDCQAZCOKTP-UHFFFAOYSA-N 0.000 description 2
• 229910052709 silver Inorganic materials 0.000 description 2
• 239000004332 silver Substances 0.000 description 2
• HKZLPVFGJNLROG-UHFFFAOYSA-M silver monochloride Chemical compound [Cl-].[Ag+] HKZLPVFGJNLROG-UHFFFAOYSA-M 0.000 description 2
• 150000003384 small molecules Chemical class 0.000 description 2
• WRIKHQLVHPKCJU-UHFFFAOYSA-N sodium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([Na])[Si](C)(C)C WRIKHQLVHPKCJU-UHFFFAOYSA-N 0.000 description 2
• 238000010561 standard procedure Methods 0.000 description 2
• 238000003860 storage Methods 0.000 description 2
• 238000006467 substitution reaction Methods 0.000 description 2
• GFYHSKONPJXCDE-UHFFFAOYSA-N sym-collidine Natural products CC1=CN=C(C)C(C)=C1 GFYHSKONPJXCDE-UHFFFAOYSA-N 0.000 description 2
• QKSQWQOAUQFORH-UHFFFAOYSA-N tert-butyl n-[(2-methylpropan-2-yl)oxycarbonylimino]carbamate Chemical compound CC(C)(C)OC(=O)N=NC(=O)OC(C)(C)C QKSQWQOAUQFORH-UHFFFAOYSA-N 0.000 description 2
• 238000002560 therapeutic procedure Methods 0.000 description 2
• FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
• 231100000331 toxic Toxicity 0.000 description 2
• 230000002588 toxic effect Effects 0.000 description 2
• 230000009466 transformation Effects 0.000 description 2
• 238000002054 transplantation Methods 0.000 description 2
• GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
• ZMAHCPKWJSLWEH-QGZVFWFLSA-N (2r)-2-[4-(3-chloro-4-pyridin-2-yloxyanilino)quinazolin-5-yl]oxy-n-(2-methoxyethyl)-n-methylpropanamide Chemical compound C=12C(O[C@H](C)C(=O)N(C)CCOC)=CC=CC2=NC=NC=1NC(C=C1Cl)=CC=C1OC1=CC=CC=N1 ZMAHCPKWJSLWEH-QGZVFWFLSA-N 0.000 description 1
• GWFUBXUZJFABMV-CYBMUJFWSA-N (2r)-2-[4-(3-chloro-4-pyridin-2-yloxyanilino)quinazolin-5-yl]oxypropanoic acid Chemical compound C=12C(O[C@H](C)C(O)=O)=CC=CC2=NC=NC=1NC(C=C1Cl)=CC=C1OC1=CC=CC=N1 GWFUBXUZJFABMV-CYBMUJFWSA-N 0.000 description 1
• QAZOKRQIRVUVAX-OAHLLOKOSA-N (2r)-2-[4-(3-methyl-4-pyridin-2-yloxyanilino)quinazolin-5-yl]oxypropanoic acid Chemical compound C=12C(O[C@H](C)C(O)=O)=CC=CC2=NC=NC=1NC(C=C1C)=CC=C1OC1=CC=CC=N1 QAZOKRQIRVUVAX-OAHLLOKOSA-N 0.000 description 1
• QDHNOYPCQADHDW-OAHLLOKOSA-N (2r)-2-[4-[3-chloro-4-(1,3-thiazol-5-yloxy)anilino]quinazolin-5-yl]oxy-1-morpholin-4-ylpropan-1-one Chemical compound O([C@H](C)C(=O)N1CCOCC1)C(C=12)=CC=CC2=NC=NC=1NC(C=C1Cl)=CC=C1OC1=CN=CS1 QDHNOYPCQADHDW-OAHLLOKOSA-N 0.000 description 1
• ODBSSWNSVZQHTQ-CQSZACIVSA-N (2r)-2-[4-[3-chloro-4-(pyridin-2-ylmethoxy)anilino]quinazolin-5-yl]oxypropanoic acid Chemical compound C=12C(O[C@H](C)C(O)=O)=CC=CC2=NC=NC=1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 ODBSSWNSVZQHTQ-CQSZACIVSA-N 0.000 description 1
• UHXLCYNHLMZSRW-OAHLLOKOSA-N (2r)-2-[4-[3-methoxy-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-5-yl]oxypropanoic acid Chemical compound COC1=CC(NC=2C3=C(O[C@H](C)C(O)=O)C=CC=C3N=CN=2)=CC=C1OC1=CC=C(C)N=C1 UHXLCYNHLMZSRW-OAHLLOKOSA-N 0.000 description 1
• XJHISJBSZUYOKF-MRXNPFEDSA-N (2r)-2-[4-[3-methyl-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-5-yl]oxypropanoic acid Chemical compound C=12C(O[C@H](C)C(O)=O)=CC=CC2=NC=NC=1NC(C=C1C)=CC=C1OC1=CC=C(C)N=C1 XJHISJBSZUYOKF-MRXNPFEDSA-N 0.000 description 1
• ODBSSWNSVZQHTQ-AWEZNQCLSA-N (2s)-2-[4-[3-chloro-4-(pyridin-2-ylmethoxy)anilino]quinazolin-5-yl]oxypropanoic acid Chemical compound C=12C(O[C@@H](C)C(O)=O)=CC=CC2=NC=NC=1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 ODBSSWNSVZQHTQ-AWEZNQCLSA-N 0.000 description 1
• SHUGRJASNGVPQD-FQEVSTJZSA-N (2s)-2-[4-[3-methyl-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-5-yl]oxy-1-morpholin-4-ylpropan-1-one Chemical compound O([C@@H](C)C(=O)N1CCOCC1)C(C=12)=CC=CC2=NC=NC=1NC(C=C1C)=CC=C1OC1=CC=C(C)N=C1 SHUGRJASNGVPQD-FQEVSTJZSA-N 0.000 description 1
• XJHISJBSZUYOKF-INIZCTEOSA-N (2s)-2-[4-[3-methyl-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-5-yl]oxypropanoic acid Chemical compound C=12C(O[C@@H](C)C(O)=O)=CC=CC2=NC=NC=1NC(C=C1C)=CC=C1OC1=CC=C(C)N=C1 XJHISJBSZUYOKF-INIZCTEOSA-N 0.000 description 1
• 125000003363 1,3,5-triazinyl group Chemical group N1=C(N=CN=C1)* 0.000 description 1
• 125000005871 1,3-benzodioxolyl group Chemical group 0.000 description 1
• ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
• LLAPDLPYIYKTGQ-UHFFFAOYSA-N 1-aminoethyl Chemical group C[CH]N LLAPDLPYIYKTGQ-UHFFFAOYSA-N 0.000 description 1
• 125000001478 1-chloroethyl group Chemical group [H]C([H])([H])C([H])(Cl)* 0.000 description 1
• 125000004066 1-hydroxyethyl group Chemical group [H]OC([H])([*])C([H])([H])[H] 0.000 description 1
• LDKSCZJUIURGMW-UHFFFAOYSA-N 1-isothiocyanato-3-methylsulfanylpropane Chemical group CSCCCN=C=S LDKSCZJUIURGMW-UHFFFAOYSA-N 0.000 description 1
• JQCSUVJDBHJKNG-UHFFFAOYSA-N 1-methoxy-ethyl Chemical group C[CH]OC JQCSUVJDBHJKNG-UHFFFAOYSA-N 0.000 description 1
• GXVUZYLYWKWJIM-UHFFFAOYSA-N 2-(2-aminoethoxy)ethanamine Chemical compound NCCOCCN GXVUZYLYWKWJIM-UHFFFAOYSA-N 0.000 description 1
• AXOMOOKEPXCVET-UHFFFAOYSA-N 2-[4-[3-chloro-4-(pyridin-2-ylmethoxy)anilino]quinazolin-5-yl]oxy-2-methylpropanoic acid Chemical compound C=12C(OC(C)(C)C(O)=O)=CC=CC2=NC=NC=1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 AXOMOOKEPXCVET-UHFFFAOYSA-N 0.000 description 1
• KEWCVXBRUWXPSD-UHFFFAOYSA-N 2-[4-[3-chloro-4-(pyridin-2-ylmethoxy)anilino]quinazolin-5-yl]oxyacetic acid Chemical compound C=12C(OCC(=O)O)=CC=CC2=NC=NC=1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 KEWCVXBRUWXPSD-UHFFFAOYSA-N 0.000 description 1
• 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 1
• 125000000143 2-carboxyethyl group Chemical group [H]OC(=O)C([H])([H])C([H])([H])* 0.000 description 1
• 125000003006 2-dimethylaminoethyl group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
• 125000004777 2-fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 description 1
• LQWQUKZCWUPLGW-UHFFFAOYSA-N 2-methyl-2-[4-[3-methyl-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-5-yl]oxypropanoic acid Chemical compound C1=NC(C)=CC=C1OC(C(=C1)C)=CC=C1NC1=NC=NC2=CC=CC(OC(C)(C)C(O)=O)=C12 LQWQUKZCWUPLGW-UHFFFAOYSA-N 0.000 description 1
• RFUBUFMTVVQVSS-UHFFFAOYSA-N 2-methyl-2-[4-[3-methyl-4-(pyridin-2-ylmethoxy)anilino]quinazolin-5-yl]oxypropanoic acid Chemical compound CC1=CC(NC=2C3=C(OC(C)(C)C(O)=O)C=CC=C3N=CN=2)=CC=C1OCC1=CC=CC=N1 RFUBUFMTVVQVSS-UHFFFAOYSA-N 0.000 description 1
• IQUPABOKLQSFBK-UHFFFAOYSA-N 2-nitrophenol Chemical compound OC1=CC=CC=C1[N+]([O-])=O IQUPABOKLQSFBK-UHFFFAOYSA-N 0.000 description 1
• 125000004637 2-oxopiperidinyl group Chemical group O=C1N(CCCC1)* 0.000 description 1
• BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
• IITIZHOBOIBGBW-UHFFFAOYSA-N 3-ethyl-2h-1,3-benzothiazole Chemical compound C1=CC=C2N(CC)CSC2=C1 IITIZHOBOIBGBW-UHFFFAOYSA-N 0.000 description 1
• 125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
• RGUKYNXWOWSRET-UHFFFAOYSA-N 4-pyrrolidin-1-ylpyridine Chemical compound C1CCCN1C1=CC=NC=C1 RGUKYNXWOWSRET-UHFFFAOYSA-N 0.000 description 1
• VQZRVPWIZFFSQD-UHFFFAOYSA-N 6h-quinazolin-5-one Chemical compound C1=NC=C2C(=O)CC=CC2=N1 VQZRVPWIZFFSQD-UHFFFAOYSA-N 0.000 description 1
• 125000003341 7 membered heterocyclic group Chemical group 0.000 description 1
• 229920001817 Agar Polymers 0.000 description 1
• 239000012103 Alexa Fluor 488 Substances 0.000 description 1
• 201000001320 Atherosclerosis Diseases 0.000 description 1
• 206010005003 Bladder cancer Diseases 0.000 description 1
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
• 241000283707 Capra Species 0.000 description 1
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
• 108091006146 Channels Proteins 0.000 description 1
• VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
• 206010009944 Colon cancer Diseases 0.000 description 1
• 102000018832 Cytochromes Human genes 0.000 description 1
• 108010052832 Cytochromes Proteins 0.000 description 1
• 230000006820 DNA synthesis Effects 0.000 description 1
• 239000006145 Eagle's minimal essential medium Substances 0.000 description 1
• 102000044591 ErbB-4 Receptor Human genes 0.000 description 1
• 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
• 102100029951 Estrogen receptor beta Human genes 0.000 description 1
• VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
• 239000005977 Ethylene Substances 0.000 description 1
• 108700024394 Exon Proteins 0.000 description 1
• WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
• 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
• 208000032612 Glial tumor Diseases 0.000 description 1
• 206010018338 Glioma Diseases 0.000 description 1
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
• WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
• 102000003886 Glycoproteins Human genes 0.000 description 1
• 108090000288 Glycoproteins Proteins 0.000 description 1
• 101001047090 Homo sapiens Potassium voltage-gated channel subfamily H member 2 Proteins 0.000 description 1
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
• QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
• 239000002841 Lewis acid Substances 0.000 description 1
• 241000699660 Mus musculus Species 0.000 description 1
• 108010052185 Myotonin-Protein Kinase Proteins 0.000 description 1
• 102000018658 Myotonin-Protein Kinase Human genes 0.000 description 1
• PVCJKHHOXFKFRP-UHFFFAOYSA-N N-acetylethanolamine Chemical compound CC(=O)NCCO PVCJKHHOXFKFRP-UHFFFAOYSA-N 0.000 description 1
• 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 1
• 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
• PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 1
• GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
• 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
• 241000283973 Oryctolagus cuniculus Species 0.000 description 1
• 206010033128 Ovarian cancer Diseases 0.000 description 1
• 206010061535 Ovarian neoplasm Diseases 0.000 description 1
• KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 1
• 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
• 229920005439 Perspex® Polymers 0.000 description 1
• 108010001441 Phosphopeptides Proteins 0.000 description 1
• 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
• 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
• OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
• 206010060862 Prostate cancer Diseases 0.000 description 1
• 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
• 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
• 102000001253 Protein Kinase Human genes 0.000 description 1
• 108010072960 Proto-Oncogene Proteins c-fyn Proteins 0.000 description 1
• 102000007131 Proto-Oncogene Proteins c-fyn Human genes 0.000 description 1
• 108010021833 Proto-Oncogene Proteins c-yes Proteins 0.000 description 1
• 229940127361 Receptor Tyrosine Kinase Inhibitors Drugs 0.000 description 1
• 101710100963 Receptor tyrosine-protein kinase erbB-4 Proteins 0.000 description 1
• 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
• 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
• 208000015634 Rectal Neoplasms Diseases 0.000 description 1
• 208000005718 Stomach Neoplasms Diseases 0.000 description 1
• 229910021626 Tin(II) chloride Inorganic materials 0.000 description 1
• GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
• 102100021788 Tyrosine-protein kinase Yes Human genes 0.000 description 1
• 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
• 108091008605 VEGF receptors Proteins 0.000 description 1
• 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 1
• 230000005856 abnormality Effects 0.000 description 1
• 238000011481 absorbance measurement Methods 0.000 description 1
• 108010076089 accutase Proteins 0.000 description 1
• 229960000583 acetic acid Drugs 0.000 description 1
• 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 description 1
• 239000003377 acid catalyst Substances 0.000 description 1
• 230000002378 acidificating effect Effects 0.000 description 1
• 150000007513 acids Chemical class 0.000 description 1
• 125000003647 acryloyl group Chemical group O=C([*])C([H])=C([H])[H] 0.000 description 1
• 230000009471 action Effects 0.000 description 1
• 230000004913 activation Effects 0.000 description 1
• 150000001266 acyl halides Chemical class 0.000 description 1
• 125000005041 acyloxyalkyl group Chemical group 0.000 description 1
• 238000007259 addition reaction Methods 0.000 description 1
• 208000009956 adenocarcinoma Diseases 0.000 description 1
• 230000002411 adverse Effects 0.000 description 1
• 239000008272 agar Substances 0.000 description 1
• 235000004279 alanine Nutrition 0.000 description 1
• 125000001931 aliphatic group Chemical group 0.000 description 1
• 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
• 150000001342 alkaline earth metals Chemical class 0.000 description 1
• 150000001350 alkyl halides Chemical class 0.000 description 1
• 125000005278 alkyl sulfonyloxy group Chemical group 0.000 description 1
• 230000002152 alkylating effect Effects 0.000 description 1
• 230000029936 alkylation Effects 0.000 description 1
• 238000005804 alkylation reaction Methods 0.000 description 1
• 125000001118 alkylidene group Chemical group 0.000 description 1
• 125000005336 allyloxy group Chemical group 0.000 description 1
• 235000001014 amino acid Nutrition 0.000 description 1
• 230000003321 amplification Effects 0.000 description 1
• 239000012491 analyte Substances 0.000 description 1
• 230000001093 anti-cancer Effects 0.000 description 1
• 229940124650 anti-cancer therapies Drugs 0.000 description 1
• 238000011319 anticancer therapy Methods 0.000 description 1
• 239000002246 antineoplastic agent Substances 0.000 description 1
• 230000006907 apoptotic process Effects 0.000 description 1
• 125000005135 aryl sulfinyl group Chemical group 0.000 description 1
• 125000004391 aryl sulfonyl group Chemical group 0.000 description 1
• 125000005279 aryl sulfonyloxy group Chemical group 0.000 description 1
• 125000005110 aryl thio group Chemical group 0.000 description 1
• 125000004104 aryloxy group Chemical group 0.000 description 1
• 239000012911 assay medium Substances 0.000 description 1
• OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 1
• 125000000751 azo group Chemical group [*]N=N[*] 0.000 description 1
• 230000009286 beneficial effect Effects 0.000 description 1
• 230000008901 benefit Effects 0.000 description 1
• PXXJHWLDUBFPOL-UHFFFAOYSA-N benzamidine Chemical compound NC(=N)C1=CC=CC=C1 PXXJHWLDUBFPOL-UHFFFAOYSA-N 0.000 description 1
• 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
• 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
• 125000004601 benzofurazanyl group Chemical group N1=C2C(=NO1)C(=CC=C2)* 0.000 description 1
• 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
• 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
• 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
• 230000002146 bilateral effect Effects 0.000 description 1
• 230000031018 biological processes and functions Effects 0.000 description 1
• 230000033228 biological regulation Effects 0.000 description 1
• 230000005540 biological transmission Effects 0.000 description 1
• 229960000074 biopharmaceutical Drugs 0.000 description 1
• 230000037396 body weight Effects 0.000 description 1
• 239000005388 borosilicate glass Substances 0.000 description 1
• 229940098773 bovine serum albumin Drugs 0.000 description 1
• 239000000872 buffer Substances 0.000 description 1
• 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
• 125000006309 butyl amino group Chemical group 0.000 description 1
• 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 239000011575 calcium Substances 0.000 description 1
• 229910052791 calcium Inorganic materials 0.000 description 1
• 230000009702 cancer cell proliferation Effects 0.000 description 1
• 208000035269 cancer or benign tumor Diseases 0.000 description 1
• 239000011545 carbonate/bicarbonate buffer Substances 0.000 description 1
• 230000015556 catabolic process Effects 0.000 description 1
• 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
• 238000006555 catalytic reaction Methods 0.000 description 1
• 230000008568 cell cell communication Effects 0.000 description 1
• 230000024245 cell differentiation Effects 0.000 description 1
• 230000010261 cell growth Effects 0.000 description 1
• 230000005754 cellular signaling Effects 0.000 description 1
• 238000005119 centrifugation Methods 0.000 description 1
• 229960005395 cetuximab Drugs 0.000 description 1
• 230000008859 change Effects 0.000 description 1
• 239000007795 chemical reaction product Substances 0.000 description 1
• 238000004587 chromatography analysis Methods 0.000 description 1
• 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
• 208000029742 colonic neoplasm Diseases 0.000 description 1
• 230000002596 correlated effect Effects 0.000 description 1
• 239000013078 crystal Substances 0.000 description 1
• 238000012136 culture method Methods 0.000 description 1
• 210000004748 cultured cell Anatomy 0.000 description 1
• 230000001186 cumulative effect Effects 0.000 description 1
• 125000001047 cyclobutenyl group Chemical group C1(=CCC1)* 0.000 description 1
• 125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 description 1
• 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
• 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
• 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
• 231100000433 cytotoxic Toxicity 0.000 description 1
• 230000001472 cytotoxic effect Effects 0.000 description 1
• 125000004652 decahydroisoquinolinyl group Chemical group C1(NCCC2CCCCC12)* 0.000 description 1
• 125000004856 decahydroquinolinyl group Chemical group N1(CCCC2CCCCC12)* 0.000 description 1
• 238000006731 degradation reaction Methods 0.000 description 1
• 239000012024 dehydrating agents‎ Substances 0.000 description 1
• 238000012217 deletion Methods 0.000 description 1
• 230000037430 deletion Effects 0.000 description 1
• 230000017858 demethylation Effects 0.000 description 1
• 230000001419 dependent effect Effects 0.000 description 1
• 238000010511 deprotection reaction Methods 0.000 description 1
• 238000001212 derivatisation Methods 0.000 description 1
• 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
• 125000006264 diethylaminomethyl group Chemical group [H]C([H])([H])C([H])([H])N(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 description 1
• 230000029087 digestion Effects 0.000 description 1
• 125000006222 dimethylaminomethyl group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])* 0.000 description 1
• ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical group C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
• 239000012153 distilled water Substances 0.000 description 1
• 231100000673 dose–response relationship Toxicity 0.000 description 1
• 229940079593 drug Drugs 0.000 description 1
• 230000002900 effect on cell Effects 0.000 description 1
• 230000007831 electrophysiology Effects 0.000 description 1
• 230000002124 endocrine Effects 0.000 description 1
• 238000005516 engineering process Methods 0.000 description 1
• 238000006345 epimerization reaction Methods 0.000 description 1
• 229940082789 erbitux Drugs 0.000 description 1
• 201000004101 esophageal cancer Diseases 0.000 description 1
• 229950002007 estradiol benzoate Drugs 0.000 description 1
• ZOSOBXDFALAPAI-UHFFFAOYSA-N ethyl 2-[4-[3-chloro-4-(pyridin-2-ylmethoxy)anilino]quinazolin-5-yl]oxyacetate Chemical compound C=12C(OCC(=O)OCC)=CC=CC2=NC=NC=1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 ZOSOBXDFALAPAI-UHFFFAOYSA-N 0.000 description 1
• 125000004672 ethylcarbonyl group Chemical group [H]C([H])([H])C([H])([H])C(*)=O 0.000 description 1
• 125000006351 ethylthiomethyl group Chemical group [H]C([H])([H])C([H])([H])SC([H])([H])* 0.000 description 1
• 125000005290 ethynyloxy group Chemical group C(#C)O* 0.000 description 1
• 210000003527 eukaryotic cell Anatomy 0.000 description 1
• 238000011156 evaluation Methods 0.000 description 1
• 238000003818 flash chromatography Methods 0.000 description 1
• 239000008098 formaldehyde solution Substances 0.000 description 1
• 239000012634 fragment Substances 0.000 description 1
• 239000012458 free base Substances 0.000 description 1
• 125000002541 furyl group Chemical group 0.000 description 1
• 239000007789 gas Substances 0.000 description 1
• 206010017758 gastric cancer Diseases 0.000 description 1
• 239000008103 glucose Substances 0.000 description 1
• 235000013922 glutamic acid Nutrition 0.000 description 1
• 239000004220 glutamic acid Substances 0.000 description 1
• 230000005484 gravity Effects 0.000 description 1
• 230000012010 growth Effects 0.000 description 1
• 239000003102 growth factor Substances 0.000 description 1
• 230000009036 growth inhibition Effects 0.000 description 1
• 201000010536 head and neck cancer Diseases 0.000 description 1
• 208000014829 head and neck neoplasm Diseases 0.000 description 1
• 229940022353 herceptin Drugs 0.000 description 1
• 210000005260 human cell Anatomy 0.000 description 1
• IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
• 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
• XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
• NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
• 230000001900 immune effect Effects 0.000 description 1
• 238000010166 immunofluorescence Methods 0.000 description 1
• 238000011065 in-situ storage Methods 0.000 description 1
• 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
• 229910052738 indium Inorganic materials 0.000 description 1
• APFVFJFRJDLVQX-UHFFFAOYSA-N indium atom Chemical compound [In] APFVFJFRJDLVQX-UHFFFAOYSA-N 0.000 description 1
• 125000001041 indolyl group Chemical group 0.000 description 1
• 230000001939 inductive effect Effects 0.000 description 1
• 230000006662 intracellular pathway Effects 0.000 description 1
• 230000031146 intracellular signal transduction Effects 0.000 description 1
• 238000011835 investigation Methods 0.000 description 1
• 125000002346 iodo group Chemical group I* 0.000 description 1
• 229940084651 iressa Drugs 0.000 description 1
• 229910052742 iron Inorganic materials 0.000 description 1
• 229960004592 isopropanol Drugs 0.000 description 1
• JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 description 1
• 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 1
• 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
• 238000000021 kinase assay Methods 0.000 description 1
• 208000032839 leukemia Diseases 0.000 description 1
• 150000007517 lewis acids Chemical class 0.000 description 1
• 239000007788 liquid Substances 0.000 description 1
• 239000012280 lithium aluminium hydride Substances 0.000 description 1
• ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 1
• 208000020816 lung neoplasm Diseases 0.000 description 1
• 159000000003 magnesium salts Chemical class 0.000 description 1
• VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
• 239000011976 maleic acid Substances 0.000 description 1
• 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
• 210000005075 mammary gland Anatomy 0.000 description 1
• 239000000463 material Substances 0.000 description 1
• 230000007246 mechanism Effects 0.000 description 1
• 229910052751 metal Inorganic materials 0.000 description 1
• 239000002184 metal Substances 0.000 description 1
• 150000002739 metals Chemical class 0.000 description 1
• 125000005948 methanesulfonyloxy group Chemical group 0.000 description 1
• 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
• VOKVQXLODBVDKS-MRXNPFEDSA-N methyl (2r)-2-[4-(3-methyl-4-pyridin-2-yloxyanilino)quinazolin-5-yl]oxypropanoate Chemical compound C=12C(O[C@H](C)C(=O)OC)=CC=CC2=NC=NC=1NC(C=C1C)=CC=C1OC1=CC=CC=N1 VOKVQXLODBVDKS-MRXNPFEDSA-N 0.000 description 1
• ULFPNBOKLQPJGV-OAHLLOKOSA-N methyl (2r)-2-[4-[3-chloro-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-5-yl]oxypropanoate Chemical compound C=12C(O[C@H](C)C(=O)OC)=CC=CC2=NC=NC=1NC(C=C1Cl)=CC=C1OC1=CC=C(C)N=C1 ULFPNBOKLQPJGV-OAHLLOKOSA-N 0.000 description 1
• YHHUWJPCYHQTSV-OAHLLOKOSA-N methyl (2r)-2-[4-[3-chloro-4-(pyridin-2-ylmethoxy)anilino]quinazolin-5-yl]oxypropanoate Chemical compound C=12C(O[C@H](C)C(=O)OC)=CC=CC2=NC=NC=1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 YHHUWJPCYHQTSV-OAHLLOKOSA-N 0.000 description 1
• ZYAQKSIEJHIWJO-MRXNPFEDSA-N methyl (2r)-2-[4-[3-methoxy-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-5-yl]oxypropanoate Chemical compound C=12C(O[C@H](C)C(=O)OC)=CC=CC2=NC=NC=1NC(C=C1OC)=CC=C1OC1=CC=C(C)N=C1 ZYAQKSIEJHIWJO-MRXNPFEDSA-N 0.000 description 1
• NBDKYGHMFBTRLR-QGZVFWFLSA-N methyl (2r)-2-[4-[3-methyl-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-5-yl]oxypropanoate Chemical compound C=12C(O[C@H](C)C(=O)OC)=CC=CC2=NC=NC=1NC(C=C1C)=CC=C1OC1=CC=C(C)N=C1 NBDKYGHMFBTRLR-QGZVFWFLSA-N 0.000 description 1
• RWVBQNQYSPMONT-QGZVFWFLSA-N methyl (2r)-2-[4-[3-methyl-4-(pyridin-2-ylmethoxy)anilino]quinazolin-5-yl]oxypropanoate Chemical compound C=12C(O[C@H](C)C(=O)OC)=CC=CC2=NC=NC=1NC(C=C1C)=CC=C1OCC1=CC=CC=N1 RWVBQNQYSPMONT-QGZVFWFLSA-N 0.000 description 1
• YHHUWJPCYHQTSV-HNNXBMFYSA-N methyl (2s)-2-[4-[3-chloro-4-(pyridin-2-ylmethoxy)anilino]quinazolin-5-yl]oxypropanoate Chemical compound C=12C(O[C@@H](C)C(=O)OC)=CC=CC2=NC=NC=1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 YHHUWJPCYHQTSV-HNNXBMFYSA-N 0.000 description 1
• NBDKYGHMFBTRLR-KRWDZBQOSA-N methyl (2s)-2-[4-[3-methyl-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-5-yl]oxypropanoate Chemical compound C=12C(O[C@@H](C)C(=O)OC)=CC=CC2=NC=NC=1NC(C=C1C)=CC=C1OC1=CC=C(C)N=C1 NBDKYGHMFBTRLR-KRWDZBQOSA-N 0.000 description 1
• 125000004674 methylcarbonyl group Chemical group CC(=O)* 0.000 description 1
• 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
• 125000006216 methylsulfinyl group Chemical group [H]C([H])([H])S(*)=O 0.000 description 1
• 125000004092 methylthiomethyl group Chemical group [H]C([H])([H])SC([H])([H])* 0.000 description 1
• 230000000394 mitotic effect Effects 0.000 description 1
• 230000037230 mobility Effects 0.000 description 1
• 239000003068 molecular probe Substances 0.000 description 1
• 125000004312 morpholin-2-yl group Chemical group [H]N1C([H])([H])C([H])([H])OC([H])(*)C1([H])[H] 0.000 description 1
• PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 1
• AHLKSOXEVRYIRD-UHFFFAOYSA-N n-phenylquinazolin-2-amine Chemical group N=1C=C2C=CC=CC2=NC=1NC1=CC=CC=C1 AHLKSOXEVRYIRD-UHFFFAOYSA-N 0.000 description 1
• 125000001624 naphthyl group Chemical group 0.000 description 1
• 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
• CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical group C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
• 201000011216 nasopharynx carcinoma Diseases 0.000 description 1
• 229910017604 nitric acid Inorganic materials 0.000 description 1
• 210000004882 non-tumor cell Anatomy 0.000 description 1
• 238000003199 nucleic acid amplification method Methods 0.000 description 1
• 239000012038 nucleophile Substances 0.000 description 1
• 239000002773 nucleotide Substances 0.000 description 1
• 125000003729 nucleotide group Chemical group 0.000 description 1
• 229920002113 octoxynol Polymers 0.000 description 1
• 150000007530 organic bases Chemical class 0.000 description 1
• 238000006053 organic reaction Methods 0.000 description 1
• 239000003960 organic solvent Substances 0.000 description 1
• 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
• 210000001672 ovary Anatomy 0.000 description 1
• 125000005961 oxazepanyl group Chemical group 0.000 description 1
• 230000003647 oxidation Effects 0.000 description 1
• 238000007254 oxidation reaction Methods 0.000 description 1
• 125000000466 oxiranyl group Chemical group 0.000 description 1
• 125000005476 oxopyrrolidinyl group Chemical group 0.000 description 1
• PLIKAWJENQZMHA-UHFFFAOYSA-N p-hydroxyphenylamine Natural products NC1=CC=C(O)C=C1 PLIKAWJENQZMHA-UHFFFAOYSA-N 0.000 description 1
• 125000006503 p-nitrobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1[N+]([O-])=O)C([H])([H])* 0.000 description 1
• 238000010979 pH adjustment Methods 0.000 description 1
• 201000002528 pancreatic cancer Diseases 0.000 description 1
• 208000008443 pancreatic carcinoma Diseases 0.000 description 1
• 230000036961 partial effect Effects 0.000 description 1
• 238000012402 patch clamp technique Methods 0.000 description 1
• 230000037361 pathway Effects 0.000 description 1
• 238000005897 peptide coupling reaction Methods 0.000 description 1
• 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
• 230000010412 perfusion Effects 0.000 description 1
• 230000002093 peripheral effect Effects 0.000 description 1
• 238000003566 phosphorylation assay Methods 0.000 description 1
• DCWXELXMIBXGTH-UHFFFAOYSA-N phosphotyrosine Chemical compound OC(=O)C(N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-UHFFFAOYSA-N 0.000 description 1
• 238000001782 photodegradation Methods 0.000 description 1
• 125000005633 phthalidyl group Chemical group 0.000 description 1
• 125000004574 piperidin-2-yl group Chemical group N1C(CCCC1)* 0.000 description 1
• 125000004483 piperidin-3-yl group Chemical group N1CC(CCC1)* 0.000 description 1
• 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 description 1
• BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 1
• 239000004926 polymethyl methacrylate Substances 0.000 description 1
• 102000054765 polymorphisms of proteins Human genes 0.000 description 1
• 229920001184 polypeptide Polymers 0.000 description 1
• XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
• NTTOTNSKUYCDAV-UHFFFAOYSA-N potassium hydride Chemical compound [KH] NTTOTNSKUYCDAV-UHFFFAOYSA-N 0.000 description 1
• 229910000105 potassium hydride Inorganic materials 0.000 description 1
• 239000000843 powder Substances 0.000 description 1
• 238000004393 prognosis Methods 0.000 description 1
• WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical group CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 1
• 125000004673 propylcarbonyl group Chemical group 0.000 description 1
• 125000004742 propyloxycarbonyl group Chemical group 0.000 description 1
• 108060006633 protein kinase Proteins 0.000 description 1
• 238000000746 purification Methods 0.000 description 1
• AOJFQRQNPXYVLM-UHFFFAOYSA-N pyridin-1-ium;chloride Chemical compound [Cl-].C1=CC=[NH+]C=C1 AOJFQRQNPXYVLM-UHFFFAOYSA-N 0.000 description 1
• 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 description 1
• 125000000168 pyrrolyl group Chemical group 0.000 description 1
• 238000011002 quantification Methods 0.000 description 1
• 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
• 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
• 230000006340 racemization Effects 0.000 description 1
• 150000003254 radicals Chemical class 0.000 description 1
• 229920005604 random copolymer Polymers 0.000 description 1
• 238000011084 recovery Methods 0.000 description 1
• 206010038038 rectal cancer Diseases 0.000 description 1
• 201000001275 rectum cancer Diseases 0.000 description 1
• 238000010992 reflux Methods 0.000 description 1
• 230000025053 regulation of cell proliferation Effects 0.000 description 1
• 230000008844 regulatory mechanism Effects 0.000 description 1
• BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
• 230000010076 replication Effects 0.000 description 1
• 208000037803 restenosis Diseases 0.000 description 1
• 230000000717 retained effect Effects 0.000 description 1
• 230000002441 reversible effect Effects 0.000 description 1
• 238000005070 sampling Methods 0.000 description 1
• 238000003118 sandwich ELISA Methods 0.000 description 1
• 230000003248 secreting effect Effects 0.000 description 1
• 238000000926 separation method Methods 0.000 description 1
• 125000003808 silyl group Chemical group [H][Si]([H])([H])[*] 0.000 description 1
• 235000020183 skimmed milk Nutrition 0.000 description 1
• 229910052708 sodium Inorganic materials 0.000 description 1
• JVBXVOWTABLYPX-UHFFFAOYSA-L sodium dithionite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])=O JVBXVOWTABLYPX-UHFFFAOYSA-L 0.000 description 1
• QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
• 235000009518 sodium iodide Nutrition 0.000 description 1
• RZWQDAUIUBVCDD-UHFFFAOYSA-M sodium;benzenethiolate Chemical compound [Na+].[S-]C1=CC=CC=C1 RZWQDAUIUBVCDD-UHFFFAOYSA-M 0.000 description 1
• 238000009331 sowing Methods 0.000 description 1
• 230000006641 stabilisation Effects 0.000 description 1
• 238000011105 stabilization Methods 0.000 description 1
• 235000011150 stannous chloride Nutrition 0.000 description 1
• 230000000638 stimulation Effects 0.000 description 1
• 239000011550 stock solution Substances 0.000 description 1
• 210000002784 stomach Anatomy 0.000 description 1
• 201000011549 stomach cancer Diseases 0.000 description 1
• 238000010254 subcutaneous injection Methods 0.000 description 1
• 239000007929 subcutaneous injection Substances 0.000 description 1
• PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical class [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 description 1
• 150000003462 sulfoxides Chemical class 0.000 description 1
• 125000004434 sulfur atom Chemical group 0.000 description 1
• 239000006228 supernatant Substances 0.000 description 1
• 238000012353 t test Methods 0.000 description 1
• 125000006253 t-butylcarbonyl group Chemical group [H]C([H])([H])C(C(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• 229940120982 tarceva Drugs 0.000 description 1
• 125000003698 tetramethyl group Chemical group [H]C([H])([H])* 0.000 description 1
• 125000003831 tetrazolyl group Chemical group 0.000 description 1
• 125000001113 thiadiazolyl group Chemical group 0.000 description 1
• 125000001544 thienyl group Chemical group 0.000 description 1
• 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
• AXZWODMDQAVCJE-UHFFFAOYSA-L tin(II) chloride (anhydrous) Chemical compound [Cl-].[Cl-].[Sn+2] AXZWODMDQAVCJE-UHFFFAOYSA-L 0.000 description 1
• YONPGGFAJWQGJC-UHFFFAOYSA-K titanium(iii) chloride Chemical compound Cl[Ti](Cl)Cl YONPGGFAJWQGJC-UHFFFAOYSA-K 0.000 description 1
• VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
• 238000011830 transgenic mouse model Methods 0.000 description 1
• 102000027257 transmembrane receptors Human genes 0.000 description 1
• 108091008578 transmembrane receptors Proteins 0.000 description 1
• 229960000575 trastuzumab Drugs 0.000 description 1
• 125000004665 trialkylsilyl group Chemical group 0.000 description 1
• 125000001425 triazolyl group Chemical group 0.000 description 1
• TUQOTMZNTHZOKS-UHFFFAOYSA-N tributylphosphine Chemical compound CCCCP(CCCC)CCCC TUQOTMZNTHZOKS-UHFFFAOYSA-N 0.000 description 1
• 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
• 231100000588 tumorigenic Toxicity 0.000 description 1
• 230000000381 tumorigenic effect Effects 0.000 description 1
• 231100000402 unacceptable toxicity Toxicity 0.000 description 1
• 241000701447 unidentified baculovirus Species 0.000 description 1
• 201000005112 urinary bladder cancer Diseases 0.000 description 1
• 239000002525 vasculotropin inhibitor Substances 0.000 description 1
• 230000035899 viability Effects 0.000 description 1